

Tadeusz Robak

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4029192/publications.pdf>

Version: 2024-02-01

624
papers

24,307
citations

16437

64
h-index

10724

138
g-index

649
all docs

649
docs citations

649
times ranked

18016
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety of the Anti-CD19 antibody Tafasitamab in Long Term Responders from A Phase II Trial for Relapsed Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 270-275.	0.2	4
2	Impact of venetoclax monotherapy on the quality of life of patients with relapsed or refractory chronic lymphocytic leukemia: results from the phase 3b VENICE II trial. <i>Leukemia and Lymphoma</i> , 2022, 63, 304-314.	0.6	8
3	Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies. <i>Leukemia and Lymphoma</i> , 2022, 63, 1375-1386.	0.6	8
4	The Role of Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions. <i>Cancers</i> , 2022, 14, 771.	1.7	35
5	Leukemia cutis in accelerated chronic lymphocytic leukemia: successful treatment with venetoclax and rituximab. <i>Annals of Hematology</i> , 2022, 101, 1387-1392.	0.8	3
6	Acabrutinib: a bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia. <i>Expert Review of Hematology</i> , 2022, 15, 183-194.	1.0	7
7	New Treatment Options for Newly-Diagnosed and Relapsed Chronic Lymphocytic Leukemia. <i>Current Treatment Options in Oncology</i> , 2022, , 1.	1.3	4
8	PI3K Inhibitors for the Treatment of Chronic Lymphocytic Leukemia: Current Status and Future Perspectives. <i>Cancers</i> , 2022, 14, 1571.	1.7	17
9	Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. <i>Blood Advances</i> , 2022, 6, 3440-3450.	2.5	91
10	Pretreatment Serum Levels of IL-1 Receptor Antagonist and IL-4 Are Predictors of Overall Survival in Multiple Myeloma Patients Treated with Bortezomib. <i>Journal of Clinical Medicine</i> , 2022, 11, 112.	1.0	3
11	The influence of venetoclax, used alone or in combination with cladribine (2-CdA), on CLL cells apoptosis in vitro: Preliminary results. <i>Advances in Clinical and Experimental Medicine</i> , 2022, 31, 0-0.	0.6	0
12	Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy. <i>Blood</i> , 2022, 140, 285-289.	0.6	15
13	Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities. , 2022, 1, .		66
14	Bruton's Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives. <i>Journal of Clinical Medicine</i> , 2022, 11, 2807.	1.0	23
15	A 3-decade multicenter European experience with cladribine as upfront treatment in 384 patients with hairy cell leukemia. <i>Blood Advances</i> , 2022, 6, 4224-4227.	2.5	7
16	Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab. <i>Blood</i> , 2022, 140, 839-850.	0.6	55
17	The EHA Research Roadmap: Malignant Lymphoid Diseases. <i>HemaSphere</i> , 2022, 6, e726.	1.2	1
18	Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2022, 23, 1031-1043.	5.1	76

#	ARTICLE	IF	CITATIONS
19	Current Treatment of Refractory/Relapsed Chronic Lymphocytic Leukemia: A Focus on Novel Drugs. <i>Acta Haematologica</i> , 2021, 144, 365-379.	0.7	13
20	Multifocal osteolytic lesions in hairy cell leukemia – the importance of PET/CT in diagnosis and assessment. <i>Annals of Hematology</i> , 2021, 100, 1641-1645.	0.8	2
21	The role of NF- κ B and Smac/DIABLO proteins in the treatment response and survival of acute myeloid leukemia patients. <i>Archives of Medical Science</i> , 2021, 17, 700-707.	0.4	1
22	Skin changes in hairy cell leukemia. <i>Annals of Hematology</i> , 2021, 100, 615-625.	0.8	16
23	The management of hematologic malignancies during the COVID-19 pandemic. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 565-582.	0.9	9
24	Der Stand der Therapie bei der refraktären/rezidivierenden chronischen lymphatischen Leukämie: Neuartige Wirkstoffe im Fokus. <i>Karger Kompass Onkologie</i> , 2021, 8, 59-69.	0.0	0
25	Hairy Cell Leukemia. <i>Hematologic Malignancies</i> , 2021, , 179-194.	0.2	0
26	Advances in the pharmacotherapeutic options for primary nodal peripheral T-cell lymphoma. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1203-1215.	0.9	6
27	The Prognostic Value of Whole-Blood PSMB5, CXCR4, POMP, and RPL5 mRNA Expression in Patients with Multiple Myeloma Treated with Bortezomib. <i>Cancers</i> , 2021, 13, 951.	1.7	9
28	Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial. <i>Journal of Hematology and Oncology</i> , 2021, 14, 35.	6.9	51
29	MicroRNA in Multiple Myeloma - A Role in Pathogenesis and Prognostic Significance. <i>Current Medicinal Chemistry</i> , 2021, 28, 6753-6772.	1.2	5
30	Cutaneous leukocytoclastic vasculitis at diagnosis of hairy cell leukemia successfully treated with vemurafenib and rituximab. <i>Leukemia Research</i> , 2021, 104, 106571.	0.4	2
31	Hairy cell leukemia and COVID-19 adaptation of treatment guidelines. <i>Leukemia</i> , 2021, 35, 1864-1872.	3.3	28
32	IDH2 mutations in patients with normal karyotype AML predict favorable responses to daunorubicin, cytarabine and cladribine regimen. <i>Scientific Reports</i> , 2021, 11, 10017.	1.6	3
33	Vemurafenib and Rituximab in Patients with Hairy Cell Leukemia Previously Treated with Moxetumomab Pasudotox. <i>Journal of Clinical Medicine</i> , 2021, 10, 2800.	1.0	13
34	Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 3441-3452.	0.8	266
35	Hairy cell leukemia: a brief update on current knowledge and treatment prospects. <i>Current Opinion in Oncology</i> , 2021, 33, 412-419.	1.1	5
36	Idelalisib immune-related toxicity is associated with improved treatment response. <i>Leukemia and Lymphoma</i> , 2021, 62, 1-6.	0.6	10

#	ARTICLE	IF	CITATIONS
37	Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia. <i>Nature Communications</i> , 2021, 12, 5395.	5.8	15
38	Zanubrutinib monotherapy for patients with treatment-naïve chronic lymphocytic leukemia and 17p deletion. <i>Haematologica</i> , 2021, 106, 2354-2363.	1.7	62
39	Prognostic Value of Resistance Proteins in Plasma Cells from Multiple Myeloma Patients Treated with Bortezomib-Based Regimens. <i>Journal of Clinical Medicine</i> , 2021, 10, 5028.	1.0	1
40	The Significance of mRNA in the Biology of Multiple Myeloma and Its Clinical Implications. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12070.	1.8	3
41	SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib versus Bendamustine + Rituximab (BR) in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). <i>Blood</i> , 2021, 138, 396-396.	0.6	22
42	OCEAN (OP-103): Melflufen Plus Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM) - Renal Impairment (RI) Analysis. <i>Blood</i> , 2021, 138, 4777-4777.	0.6	1
43	First Prospective Data on Minimal Residual Disease (MRD) Outcomes after Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O) for First-Line Treatment of CLL in Elderly or Unfit Patients: The Glow Study. <i>Blood</i> , 2021, 138, 70-70.	0.6	20
44	Zanubrutinib in Combination with Venetoclax for Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Early Results from Arm D of the SEQUOIA (BGB-3111-304) Trial. <i>Blood</i> , 2021, 138, 67-67.	0.6	19
45	Clinical Outcomes in Patients (Pts) with Dose Reduction of Selinexor in Combination with Bortezomib, and Dexamethasone (XVd) in Previously Treated Multiple Myeloma from the Boston Study. <i>Blood</i> , 2021, 138, 3793-3793.	0.6	6
46	Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. <i>Leukemia</i> , 2020, 34, 787-798.	3.3	321
47	Early induction intensification with cladribine, cytarabine, and mitoxantrone (CLAM) in AML patients treated with the DAC induction regimen: a prospective, non-randomized, phase II study of the Polish Adult Leukemia Group (PALG). <i>Leukemia and Lymphoma</i> , 2020, 61, 588-603.	0.6	1
48	Cereblon (CRBN) gene polymorphisms predict clinical response and progression-free survival in relapsed/refractory multiple myeloma patients treated with lenalidomide: a pharmacogenetic study from the IMMEnSE consortium. <i>Leukemia and Lymphoma</i> , 2020, 61, 699-706.	0.6	3
49	Minimizing and managing treatment-associated complications in patients with chronic lymphocytic leukemia. <i>Expert Review of Hematology</i> , 2020, 13, 39-53.	1.0	6
50	Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 4042-4054.	0.8	141
51	Risk factors for grade 3/4 transaminase elevation in patients with chronic lymphocytic leukemia treated with idelalisib. <i>Leukemia</i> , 2020, 34, 3404-3407.	3.3	7
52	Long-term Efficacy of Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of the Polish Adult Leukemia Study Group Observational Study. <i>Anticancer Research</i> , 2020, 40, 4059-4066.	0.5	8
53	Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy. <i>Journal of Hematology and Oncology</i> , 2020, 13, 92.	6.9	28
54	Bone lesions in hairy cell leukemia: Diagnosis and treatment. <i>European Journal of Haematology</i> , 2020, 105, 682-691.	1.1	12

#	ARTICLE	IF	CITATIONS
55	The safety of available chemo-free treatments for mantle cell lymphoma. Expert Opinion on Drug Safety, 2020, 19, 1377-1393.	1.0	3
56	The Value of Serum MicroRNA Expression Signature in Predicting Refractoriness to Bortezomib-Based Therapy in Multiple Myeloma Patients. Cancers, 2020, 12, 2569.	1.7	21
57	Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia. Blood Advances, 2020, 4, 4136-4146.	2.5	60
58	Investigational treatments for chronic lymphocytic leukemia: a focus on phase 1 and 2 clinical trials. Expert Opinion on Investigational Drugs, 2020, 29, 709-722.	1.9	6
59	A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. Haematologica, 2020, 105, e164-e168.	1.7	5
60	Cytokine and Chemokine Profile in Patients with Multiple Myeloma Treated with Bortezomib. Mediators of Inflammation, 2020, 2020, 1-13.	1.4	18
61	A 5-year follow-up to evaluate the efficacy and safety of ofatumumab added to fludarabine and cyclophosphamide in patients with relapsed chronic lymphocytic leukemia: final analysis of the COMPLEMENT 2 trial. Leukemia and Lymphoma, 2020, 61, 1748-1751.	0.6	2
62	The up-to-date role of biologics for the treatment of chronic lymphocytic leukemia. Expert Opinion on Biological Therapy, 2020, 20, 799-812.	1.4	5
63	A five-year follow-up of untreated patients with chronic lymphocytic leukaemia treated with ofatumumab and chlorambucil: final analysis of the Complement 1 phase 3 trial. British Journal of Haematology, 2020, 190, 736-740.	1.2	9
64	Zanubrutinib in Combination with Venetoclax for Patients with Treatment-Naïve Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and del(17p): Arm D of the SEQUOIA (BGB-3111-304) Trial. Blood, 2020, 136, 24-25.	0.6	3
65	Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Follow-up Results from Arm C of the SEQUOIA (BGB-3111-304) Trial. Blood, 2020, 136, 11-12.	0.6	19
66	Efficacy of Subsequent Novel Targeted Therapies, Including Repeated Venetoclax-Rituximab (VenR), in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Previously Treated with Fixed-Duration Venr in the Murano Study. Blood, 2020, 136, 44-45.	0.6	15
67	Glasdegib (GLAS) plus low-dose cytarabine (LDAC) in AML or MDS: BRIGHT AML 1003 final report and four-year overall survival (OS) follow-up.. Journal of Clinical Oncology, 2020, 38, 7509-7509.	0.8	10
68	Escalated dosing schedules of CC-486 for patients experiencing first acute myeloid leukemia (AML) relapse: Results from the phase III QUAZAR AML-001 maintenance trial.. Journal of Clinical Oncology, 2020, 38, 7513-7513.	0.8	2
69	An Open Label, Phase 2 Study to Assess the Efficacy and Safety of Tenisib (RP6530), a PI3K $\hat{\imath}$ 3 and SIK3 Inhibitor, in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). Blood, 2020, 136, 25-25.	0.6	1
70	Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Long-Term Efficacy and Safety Results from a Phase 2 Study. Blood, 2020, 136, 38-39.	0.6	5
71	Early Mortality in Patients with Multiple Myeloma Treated with Novel Agents - Analysis from Polish Myeloma Study Group. Blood, 2020, 136, 36-37.	0.6	0
72	A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in Acute Myeloid Leukemia (AML) Patients $\hat{\%}$ 60 Years Old (PALG-AML1/2016). Blood, 2020, 136, 3-4.	0.6	0

#	ARTICLE	IF	CITATIONS
73	The Prosid Study: Evaluating Efficacy and Safety of Intravenous Immunoglobulin (IVIg) 10% in Primary Infection Prophylaxis in Patients with Chronic Lymphocytic Leukemia- Study Design. <i>Blood</i> , 2020, 136, 20-21.	0.6	1
74	Outcomes of First-Line Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and High-Risk Genomic Features with up to 6.5 Years Follow-up: Integrated Analysis of Two Phase 3 Studies (RESONATE-2 and iLLUMINATE). <i>Blood</i> , 2020, 136, 25-26.	0.6	4
75	Clinical management of mantle cell lymphoma in the elderly. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1893-1905.	0.9	3
76	Safety and Efficacy of Acalabrutinib Plus Bendamustine and Rituximab (BR) in Patients with Treatment-Naïve (TN) or Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S317.	0.2	1
77	Autoimmune thrombocytopenia: Current treatment options in adults with a focus on novel drugs. <i>European Journal of Haematology</i> , 2019, 103, 531-541.	1.1	21
78	Long-Term Follow-Up of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S316.	0.2	3
79	Five-Year Follow-Up After Ibrutinib Therapy for First-Line Treatment of Chronic Lymphocytic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S274.	0.2	0
80	Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma. <i>Leukemia</i> , 2019, 33, 2762-2766.	3.3	67
81	Glasdegib in the treatment of acute myeloid leukemia. <i>Future Oncology</i> , 2019, 15, 3219-3232.	1.1	16
82	Moxetumomab pasudotox for the treatment of hairy cell leukemia. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 501-508.	1.4	20
83	Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later. <i>Drugs in R and D</i> , 2019, 19, 73-92.	1.1	98
84	Mantle cell lymphoma: therapeutic options in transplant-ineligible patients. <i>Leukemia and Lymphoma</i> , 2019, 60, 2622-2634.	0.6	13
85	The Expression of the SLIT-ROBO Family in Adult Patients with Acute Myeloid Leukemia. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2019, 67, 109-123.	1.0	13
86	Venetoclax in the treatment of chronic lymphocytic leukemia. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 353-366.	1.5	27
87	Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis. <i>American Journal of Hematology</i> , 2019, 94, 554-562.	2.0	27
88	Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. <i>Blood Advances</i> , 2019, 3, 1799-1807.	2.5	90
89	Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients: results of a phase 3, randomized, controlled trial. <i>Health and Quality of Life Outcomes</i> , 2019, 17, 173.	1.0	5
90	Chronic lymphocytic leukemia. <i>HemaSphere</i> , 2019, 3, 36.	1.2	0

#	ARTICLE	IF	CITATIONS
91	Bendamustine alone or with rituximab modifies expression of apoptosis-regulating genes and proteins of CLL cells, depending on IGVH mutational status. <i>Leukemia and Lymphoma</i> , 2019, 60, 1409-1419.	0.6	0
92	Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. <i>Leukemia</i> , 2019, 33, 379-389.	3.3	396
93	Concurrent treatment with two B-cell receptor pathway inhibitors. <i>Lancet Haematology</i> , 2019, 6, e8-e9.	2.2	2
94	Safety and Tolerability of Antibody-Drug Conjugates in Cancer. <i>Drug Safety</i> , 2019, 42, 295-314.	1.4	75
95	Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2019, 393, 253-264.	6.3	187
96	Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study. <i>Leukemia and Lymphoma</i> , 2019, 60, 172-179.	0.6	11
97	Moxetumomab Pasudotox-Tdfk in Heavily Pretreated Patients with Relapsed/Refractory Hairy Cell Leukemia (HCL): Long-Term Follow-up from the Pivotal Phase 3 Trial. <i>Blood</i> , 2019, 134, 2808-2808.	0.6	8
98	Four-Year Analysis of Murano Study Confirms Sustained Benefit of Time-Limited Venetoclax-Rituximab (VenR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2019, 134, 355-355.	0.6	16
99	A Phase IIa, Open-Label, Multicenter Study of Single-Agent Tafasitamab (MOR208), an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma: Long-Term Follow-up, Final Analysis. <i>Blood</i> , 2019, 134, 4078-4078.	0.6	17
100	Long Term Nomacopan Administration Results in Complete Transfusion Independence in Previously Transfusion-Dependent PNH Patients. <i>Blood</i> , 2019, 134, 4797-4797.	0.6	2
101	Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naive Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with Del(17p): Initial Results from Arm C of the Sequoia (BGB-3111-304) Trial. <i>Blood</i> , 2019, 134, 499-499.	0.6	23
102	Results from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Naïve (TN) AML Unfit for Intensive Chemotherapy (IC) ASTRAL-1 Study: Analysis By Number of Cycles. <i>Blood</i> , 2019, 134, 2591-2591.	0.6	12
103	Rozanolixizumab, an Anti-FcRn Antibody: Final Results from a Phase II, Multiple-Dose Study in Patients with Primary Immune Thrombocytopenia. <i>Blood</i> , 2019, 134, 897-897.	0.6	5
104	Outcome of Patients with Hodgkin Lymphoma Treated with Brentuximab Vedotin for Relapse after Autologous Stem Cell Transplant: A Retrospective Analysis of the LWP-EBMT. <i>Blood</i> , 2019, 134, 4018-4018.	0.6	2
105	Long-term follow-up of previously untreated patients (pts) with chronic lymphocytic leukemia (CLL) treated with ofatumumab (OFA) and chlorambucil (CHL): Final analysis of the phase 3 COMPLEMENT 1 trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 7528-7528.	0.8	2
106	A large single-institution retrospective analysis of aggressive B-cell lymphomas according to the 2016/2017 WHO classification. <i>Advances in Clinical and Experimental Medicine</i> , 2019, 28, 1359-1365.	0.6	3
107	Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia. <i>Hematologic Malignancies</i> , 2019, , 107-119.	0.2	1
108	Wenetoklaks w leczeniu chorób układu krwiotwórczego i guzów litych. <i>Acta Haematologica Polonica</i> , 2019, 50, 41-50.	0.1	0

#	ARTICLE	IF	CITATIONS
109	The role of neuronal apoptosis inhibitory protein (NAIP) in acute myeloid leukemia patients. <i>Acta Haematologica Polonica</i> , 2019, 50, 74-80.	0.1	0
110	Progression Free Survival (PFS), and Event Free Survival (EFS) from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Na ⁺ ve (TN) AML Unfit for Intensive Chemotherapy (IC): ASTRAL-1 Study. <i>Blood</i> , 2019, 134, 4235-4235.	0.6	1
111	Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up. <i>Blood</i> , 2018, 131, 2331-2334.	0.6	64
112	miR-15a, miR-16, miR-126, miR-146a, and miR-223 expressions in autologous hematopoietic stem cell transplantation and their impact on engraftment. <i>European Journal of Haematology</i> , 2018, 100, 426-435.	1.1	10
113	Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. <i>Annals of Oncology</i> , 2018, 29, 1266-1272.	0.6	106
114	Investigational therapies targeting CD37 for the treatment of B-cell lymphoid malignancies. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 171-177.	1.9	19
115	Efficacy and safety of frontline rituximab, cyclophosphamide, doxorubicin and prednisone plus bortezomib (VR-CAP) or vincristine (R-CHOP) in a subset of newly diagnosed mantle cell lymphoma patients medically eligible for transplantation in the randomized, phase 3 LYM-3002 study. <i>Leukemia and Lymphoma</i> , 2018, 59, 896-903.	0.6	15
116	Decitabine improves response rate and prolongs progression-free survival in older patients with newly diagnosed acute myeloid leukemia and with monosomal karyotype: A subgroup analysis of the DACO-016 trial. <i>American Journal of Hematology</i> , 2018, 93, E125-E127.	2.0	15
117	Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG-CLL4 (ML-21283) trial. <i>European Journal of Haematology</i> , 2018, 100, 465-474.	1.1	7
118	iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. <i>Blood</i> , 2018, 131, 2745-2760.	0.6	1,069
119	Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2018, 378, 1107-1120.	13.9	684
120	Responses to romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapy. <i>Leukemia and Lymphoma</i> , 2018, 59, 880-887.	0.6	28
121	Efficacy and safety of B-cell receptor signaling pathway inhibitors in relapsed/refractory chronic lymphocytic leukemia: a systematic review and meta-analysis of randomized clinical trials. <i>Leukemia and Lymphoma</i> , 2018, 59, 1084-1094.	0.6	11
122	Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study. <i>Lancet Oncology</i> , The, 2018, 19, 1449-1458.	5.1	93
123	The efficacy of sapacitabine in treating patients with acute myeloid leukemia. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1835-1839.	0.9	4
124	Drug resistance in multiple myeloma. <i>Cancer Treatment Reviews</i> , 2018, 70, 199-208.	3.4	200
125	Clasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results. <i>American Journal of Hematology</i> , 2018, 93, 1301-1310.	2.0	98
126	High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies. <i>Blood</i> , 2018, 132, 892-902.	0.6	83

#	ARTICLE	IF	CITATIONS
127	Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia. <i>Leukemia</i> , 2018, 32, 1768-1777.	3.3	184
128	Survival adjusting for crossover: phase 3 study of ibrutinib vs chlorambucil in older patients with untreated chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>Haematologica</i> , 2018, 103, e249-e251.	1.7	5
129	Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies. <i>American Journal of Hematology</i> , 2018, 93, 1402-1410.	2.0	24
130	Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 803-813.e7.	0.2	32
131	Distinct Activities of Glycolytic Enzymes Identify Chronic Lymphocytic Leukemia Patients with a more Aggressive Course and Resistance to Chemo-Immunotherapy. <i>EBioMedicine</i> , 2018, 32, 125-133.	2.7	6
132	Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. <i>Haematologica</i> , 2018, 103, 1502-1510.	1.7	111
133	MURANO Trial Establishes Feasibility of Time-Limited Venetoclax-Rituximab (VenR) Combination Therapy in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2018, 132, 184-184.	0.6	8
134	Long-Term Follow-up of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma. <i>Blood</i> , 2018, 132, 2876-2876.	0.6	14
135	Safety and Efficacy of Acalabrutinib Plus Bendamustine and Rituximab (BR) in Patients with Treatment-Naïve (TN) or Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL). <i>Blood</i> , 2018, 132, 4144-4144.	0.6	5
136	Single-Agent Ibrutinib Versus Chlorambucil-Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results of a Cross-Trial Comparison. <i>Blood</i> , 2018, 132, 5565-5565.	0.6	3
137	Venetoclax Improves Quality of Life for Patients with Elapsed/Refractory Chronic Lymphocytic Leukemia. <i>Blood</i> , 2018, 132, 4858-4858.	0.6	4
138	Moxetumomab pasudotox in heavily pretreated patients with relapsed/refractory hairy cell leukemia: Results of a pivotal international study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7004-7004.	0.8	1
139	Phase 3 zanubrutinib (BGB-3111) vs bendamustine + rituximab (BR) in patients (pts) with treatment-naïve (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS7581-TPS7581.	0.8	5
140	Zalecenia Polskiej Grupy Szpiczakowej dotyczą...ce rozpoznawania i leczenia szpiczaka plazmocytoowego oraz innych dyskrazji plazmocytoowych na rok 2018/2019. <i>Acta Haematologica Polonica</i> , 2018, 49, 157-206.	0.1	4
141	Long-Term Evaluation of Efficacy and Safety of Ofatumumab Added to Fludarabine & Cyclophosphamide in Subjects with Relapsed Chronic Lymphocytic Leukemia: Final Analysis of Complement 2 Trial. <i>Blood</i> , 2018, 132, 3151-3151.	0.6	0
142	Szczepienia ochronne u dorosłych chorych na nowotwory hematologiczne oraz u chorych z asplenią... zalecenia PTHi i sekcji do spraw zakażeń, PALG. <i>Acta Haematologica Polonica</i> , 2018, 49, 93-101.	0.1	5
143	The safety profile of monoclonal antibodies for chronic lymphocytic leukemia. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 1-17.	1.0	3
144	Addition of cladribine to the standard induction treatment improves outcomes in a subset of elderly acute myeloid leukemia patients. Results of a randomized Polish Adult Leukemia Group (PALG) phase II trial. <i>American Journal of Hematology</i> , 2017, 92, 359-366.	2.0	24

#	ARTICLE	IF	CITATIONS
145	Front-line treatment of CLL in the era of novel agents. <i>Cancer Treatment Reviews</i> , 2017, 53, 70-78.	3.4	25
146	Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial). <i>Leukemia</i> , 2017, 31, 1240-1243.	3.3	26
147	Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. <i>Lancet Oncology</i> , The, 2017, 18, 297-311.	5.1	219
148	Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial. <i>Lancet Haematology</i> , the, 2017, 4, e114-e126.	2.2	181
149	Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP <i>versus</i> R-CHOP in the phase 3 LYM-3002 study. <i>Haematologica</i> , 2017, 102, 895-902.	1.7	6
150	Personalized therapy tests for the monitoring of chronic lymphocytic leukemia development. <i>Oncology Letters</i> , 2017, 13, 2079-2084.	0.8	5
151	Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. <i>Blood</i> , 2017, 129, 2612-2615.	0.6	111
152	Efficacy and toxicity of compassionate ibrutinib use in relapsed/refractory chronic lymphocytic leukemia in Poland: analysis of the Polish Adult Leukemia Group (PALG). <i>Leukemia and Lymphoma</i> , 2017, 58, 2485-2488.	0.6	34
153	The distribution and potential prognostic value of SMAD protein expression in chronic lymphocytic leukemia. <i>Tumor Biology</i> , 2017, 39, 101042831769455.	0.8	6
154	Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. <i>Blood</i> , 2017, 129, 553-560.	0.6	193
155	Randomized phase 2 study of otlertuzumab and bendamustine <i>versus</i> bendamustine in patients with relapsed chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2017, 176, 618-628.	1.2	36
156	Novel synthetic drugs currently in clinical development for chronic lymphocytic leukemia. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 1249-1265.	1.9	31
157	Will combination therapy with targeted drugs be better for achieving remission in chronic lymphocytic leukemia?. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1675-1678.	0.9	1
158	Polymorphism in IKZF1 gene affects clinical outcome in diffuse large B-cell lymphoma. <i>International Journal of Hematology</i> , 2017, 106, 794-800.	0.7	6
159	Blockage of Wnt/Catenin Signaling by Nanoparticles Reduces Survival and Proliferation of CLL Cells In Vitro – Preliminary Study. <i>Macromolecular Bioscience</i> , 2017, 17, 1700130.	2.1	11
160	Iksazomib u chorych z nawrotowym lub opornym na leczenie szpiczakiem plazmocytowym. <i>Acta Haematologica Polonica</i> , 2017, 48, 160-164.	0.1	0
161	Emerging antibody-drug conjugates for treating lymphoid malignancies. <i>Expert Opinion on Emerging Drugs</i> , 2017, 22, 259-273.	1.0	20
162	Analiza skuteczności ibrutinibu w podgrupie chorych na przewlekłą... białaczka™ limfocytową... z delecją... 17p: badanie obserwacyjne Polskiej Grupy ds. Leczenia Białaczek u Dorosłych (PALG). <i>Acta Haematologica Polonica</i> , 2017, 48, 330-337.	0.1	1

#	ARTICLE	IF	CITATIONS
163	The discovery and development of romidepsin for the treatment of T-cell lymphoma. <i>Expert Opinion on Drug Discovery</i> , 2017, 12, 1-15.	2.5	45
164	Health-related quality of life and patient-reported outcomes of ofatumumab plus fludarabine and cyclophosphamide versus fludarabine and cyclophosphamide in the COMPLEMENT 2 trial of patients with relapsed CLL. <i>Leukemia and Lymphoma</i> , 2017, 58, 1598-1606.	0.6	11
165	Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial. <i>Leukemia and Lymphoma</i> , 2017, 58, 1084-1093.	0.6	48
166	Concomitance of monosomal karyotype with at least 5 chromosomal abnormalities is associated with dismal treatment outcome of AML patients with complex karyotype – retrospective analysis of Polish Adult Leukemia Group (PALG). <i>Leukemia and Lymphoma</i> , 2017, 58, 889-897.	0.6	8
167	MGMT promoter methylation as a potential prognostic marker for acute leukemia. <i>Archives of Medical Science</i> , 2017, 6, 1433-1441.	0.4	9
168	VEGF, ANGPT1, ANGPT2, and MMP-9 expression in the autologous hematopoietic stem cell transplantation and its impact on the time to engraftment. <i>Annals of Hematology</i> , 2017, 96, 2103-2112.	0.8	21
169	The impact of agonists and antagonists of TLR3 and TLR9 on concentrations of IL-6, IL10 and sIL-2R in culture supernatants of peripheral blood mononuclear cells derived from patients with systemic lupus erythematosus. <i>Postepy Higieny I Medycyny Doswiadczalnej</i> , 2017, 71, 0-0.	0.1	8
170	Pro-Apoptotic Activity of New Honokiol/Triphenylmethane Analogues in B-Cell Lymphoid Malignancies. <i>Molecules</i> , 2016, 21, 995.	1.7	5
171	Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma. <i>Cancer</i> , 2016, 122, 2050-2056.	2.0	40
172	Intragenic Variations in BTLA Gene Influence mRNA Expression of BTLA Gene in Chronic Lymphocytic Leukemia Patients and Confer Susceptibility to Chronic Lymphocytic Leukemia. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2016, 64, 137-145.	1.0	21
173	Novel therapies under investigation for mantle cell lymphoma. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 375-380.	1.9	2
174	HLA-G and MHC Class II Protein Expression in Diffuse Large B-Cell Lymphoma. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2016, 64, 225-240.	1.0	12
175	Donor age and C1orf132/MIR29B2C determine age-related methylation signature of blood after allogeneic hematopoietic stem cell transplantation. <i>Clinical Epigenetics</i> , 2016, 8, 93.	1.8	12
176	Rekomendacje diagnostyczne i terapeutyczne dla przewlekłej, białaczki limfocytowej w 2016 r – Raport Grupy Roboczej PTHiT i PALG-CLL. <i>Acta Haematologica Polonica</i> , 2016, 47, 169-183.	0.1	1
177	In vitro antileukemic activity of novel adenosine derivatives bearing boron cluster modification. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 5076-5087.	1.4	18
178	Innovation in non-Hodgkin lymphoma drug discovery: what needs to be done?. <i>Expert Opinion on Drug Discovery</i> , 2016, 11, 1033-1045.	2.5	1
179	Zalecenia Polskiej Grupy Szpiczakowej dotyczą...ce rozpoznawania i leczenia szpiczaka plazmocytoowego oraz innych dyskracji plazmocytoowych na rok 2016. <i>Acta Haematologica Polonica</i> , 2016, 47, 39-85.	0.1	10
180	Ibrutinib in chronic lymphocytic leukaemia: alone or in combination?. <i>Lancet Oncology</i> , The, 2016, 17, 129-131.	5.1	10

#	ARTICLE	IF	CITATIONS
181	Chlorambucil for the treatment of patients with chronic lymphocytic leukemia (CLL) – a systematic review and meta-analysis of randomized trials. <i>Leukemia and Lymphoma</i> , 2016, 57, 2047-2057.	0.6	18
182	Antibody therapy alone and in combination with targeted drugs in chronic lymphocytic leukemia. <i>Seminars in Oncology</i> , 2016, 43, 280-290.	0.8	25
183	Management of Multiple Myeloma with Second-Generation Antibody-Drug Conjugates. <i>BioDrugs</i> , 2016, 30, 87-93.	2.2	7
184	Cladribine, Cytarabine and Mitoxantrone As Treatment Intensification for Patients with Acute Myeloid Leukemia with the Excess of Bone Marrow Blasts on Day 14 of the First Induction. Prospective, Multicenter Study By the Polish Adult Leukemia Group (PALG). <i>Blood</i> , 2016, 128, 213-213.	0.6	1
185	Updated Efficacy and Safety from the Phase 3 Resonate-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 234-234.	0.6	36
186	Integrated and Long-Term Safety Analysis of Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL). <i>Blood</i> , 2016, 128, 4383-4383.	0.6	7
187	Slower Engraftment in Patients with High Expression of miRNA-15a, miRNA-16, miRNA-126, miRNA-146a, miRNA-223 Prior to Autologous Stem Cell Transplantation and at Early Time after Transplantation. <i>Blood</i> , 2016, 128, 5717-5717.	0.6	1
188	Single-Agent MOR208 in Relapsed or Refractory (R-R) Non-Hodgkin's Lymphoma (NHL): Results from Diffuse Large B-Cell Lymphoma (DLBCL) and Indolent NHL Subgroups of a Phase IIa Study. <i>Blood</i> , 2016, 128, 623-623.	0.6	7
189	A Phase 2 Randomized Study of Low Dose Ara-C with or without Glasdegib (PF-04449913) in Untreated Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome. <i>Blood</i> , 2016, 128, 99-99.	0.6	36
190	Updated results of a phase III randomized, controlled study of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukemia (CLL).. <i>Journal of Clinical Oncology</i> , 2016, 34, 7515-7515.	0.8	4
191	Outcomes with ibrutinib by line of therapy in patients with CLL: Analyses from phase III data.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7520-7520.	0.8	10
192	Patterns of hepatitis B reactivation and liver test abnormalities in patients with chronic lymphocytic leukemia (CLL) treated with idelalisib plus an anti-CD20 antibody.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7533-7533.	0.8	1
193	Subgroup analyses of diffuse large B-cell lymphoma (DLBCL) and indolent lymphoma cohorts from a phase IIa study of single-agent MOR208 in patients with relapsed or refractory non-Hodgkin's lymphoma (R-R NHL).. <i>Journal of Clinical Oncology</i> , 2016, 34, 7545-7545.	0.8	0
194	A Distributed International Patient Data Registry for Hairy Cell Leukemia. <i>Blood</i> , 2016, 128, 5986-5986.	0.6	0
195	Nonconventional Gene Expression within the NF- κ B Signaling Pathway Induced By Poly(propylene)Imine Glycodendrimers in Chronic Lymphocytic Leukemia Cells. <i>Blood</i> , 2016, 128, 5595-5595.	0.6	1
196	Altered Endothelial Cells Properties and Platelets Activity in Treatment Na ⁺ -Ve Patients with Multiple Myeloma (MM) and Non-Hodgkin Lymphoma (nHL): Association with Thromboembolic Complications. <i>Blood</i> , 2016, 128, 5649-5649.	0.6	0
197	Prognostic value of thymidine kinase activity in patients with chronic lymphocytic leukemia. <i>Postepy Higieny I Medycyny Doswiadczalnej</i> , 2016, 70, 1321-1330.	0.1	4
198	Novel target to kill CLL. <i>Blood</i> , 2015, 125, 211-212.	0.6	1

#	ARTICLE	IF	CITATIONS
199	New mutation in hairy cell leukemia. <i>Blood</i> , 2015, 126, 930-931.	0.6	6
200	Human leukocyte antigenâ€‹Gâ€› polymorphisms influence the clinical outcome in diffuse largeâ€‹Bâ€›cell lymphoma. <i>Genes Chromosomes and Cancer</i> , 2015, 54, 185-193.	1.5	18
201	The kinetics of hematopoietic niche cytokines and their influence on mobilization efficacy and timing in patients with hematological malignancies. <i>Journal of Clinical Apheresis</i> , 2015, 30, 247-251.	0.7	3
202	Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2015, 373, 2425-2437.	13.9	1,261
203	Ofatumumab for treating chronic lymphocytic leukemia: a safety profile. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 1945-1959.	1.0	12
204	Bortezomib in the treatment of mantle cell lymphoma. <i>Future Oncology</i> , 2015, 11, 2807-2818.	1.1	11
205	Relationship between in vitro drug sensitivity and clinical response of patients to treatment in chronic lymphocytic leukemia. <i>International Journal of Oncology</i> , 2015, 46, 1259-1267.	1.4	6
206	Prognostic value of inhibitor of apoptosis protein family expression in patients with acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 2529-2535.	0.6	17
207	Real-life comparison of severe vascular events and other non-hematological complications in patients with chronic myeloid leukemia undergoing second-line nilotinib or dasatinib treatment. <i>Leukemia and Lymphoma</i> , 2015, 56, 2309-2314.	0.6	34
208	Cereblon expression predicts clinical response in chronic lymphocytic leukemia treated with a thalidomide/fludarabine regimen. <i>Leukemia and Lymphoma</i> , 2015, 56, 808-810.	0.6	9
209	The preclinical discovery of rituximab for the treatment of non-Hodgkinâ€™s lymphoma. <i>Expert Opinion on Drug Discovery</i> , 2015, 10, 791-808.	2.5	7
210	Emerging immunological drugs for chronic lymphocytic leukemia. <i>Expert Opinion on Emerging Drugs</i> , 2015, 20, 423-447.	1.0	9
211	Treatment of elderly patients with acute myeloid leukemia adjusted for performance status and presence of comorbidities: a Polish Adult Leukemia Group study. <i>Leukemia and Lymphoma</i> , 2015, 56, 2331-2338.	0.6	9
212	Przewlekła, a białaczka limfocytowa wysokiego ryzyka. <i>Acta Haematologica Polonica</i> , 2015, 46, 68-74.	0.1	0
213	Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. <i>Lancet, The</i> , 2015, 385, 1873-1883.	6.3	296
214	Zalecenia Polskiej Grupy Szpiczakowej dotyczące rozpoznawania i leczenia szpiczaka plazmocytoowego oraz innych dyskrazji plazmocytoowych na rok 2015. <i>Acta Haematologica Polonica</i> , 2015, 46, 159-211.	0.1	0
215	Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study. <i>Haematologica</i> , 2015, 100, e3111-4.	1.7	15
216	Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2015, 372, 944-953.	13.9	343

#	ARTICLE	IF	CITATIONS
217	Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 2847-2854.	0.6	17
218	Gene expression of INPP5F as an independent prognostic marker in fludarabine-based therapy of chronic lymphocytic leukemia. <i>Blood Cancer Journal</i> , 2015, 5, e353-e353.	2.8	8
219	Potential breakthroughs with investigational drugs for hairy cell leukemia. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 1419-1431.	1.9	10
220	Antibody-Drug Conjugates and Immunotoxins for the Treatment of Hematologic Neoplasms. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2015, , 89-128.	0.1	0
221	Pharmacodynamic considerations of small molecule targeted therapy for treating B-cell malignancies in the elderly. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 1371-1391.	1.5	6
222	Treatment options for mantle cell lymphoma. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2497-2507.	0.9	9
223	Clinical relevance of vascular endothelial growth factor type A (VEGFA) and VEGF receptor type 2 (VEGFR2) gene polymorphism in chronic lymphocytic leukemia. <i>Blood Cells, Molecules, and Diseases</i> , 2015, 54, 139-143.	0.6	10
224	Richter syndrome in chronic lymphocytic leukemia: updates on biology, clinical features and therapy. <i>Leukemia and Lymphoma</i> , 2015, 56, 1949-1958.	0.6	48
225	A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma. <i>American Journal of Hematology</i> , 2015, 90, 42-49.	2.0	116
226	Jagged-1: a new promising factor associated with favorable prognosis in patients with acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 401-406.	0.6	12
227	Decitabine Improves Response Rate and Prolongs Progression Free Survival in Older Patients with Newly Diagnosed Acute Myeloid Leukemia with Monosomal Karyotype: A Subgroup Analysis of the Daco-16 Trial. <i>Blood</i> , 2015, 126, 1336-1336.	0.6	6
228	Phase IIa Study of Single-Agent MOR208 in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma. <i>Blood</i> , 2015, 126, 1528-1528.	0.6	7
229	Health-Related Quality of Life and Patient-Reported Outcomes in Patients Receiving Ofatumumab in Combination with Fludarabine and Cyclophosphamide (FC) Versus FC Alone in the Complement 2 Trial. <i>Blood</i> , 2015, 126, 5288-5288.	0.6	5
230	Idelalisib Plus Bendamustine and Rituximab (BR) Is Superior to BR Alone in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results of a Phase 3 Randomized Double-Blind Placebo-Controlled Study. <i>Blood</i> , 2015, 126, LBA-5-LBA-5.	0.6	16
231	The international Prognostic Index for patients with CLL (CLL-IPI): An international meta-analysis.. <i>Journal of Clinical Oncology</i> , 2015, 33, 7002-7002.	0.8	10
232	Dose adherence and baseline exposure analysis of the ibrutinib 420 mg dose administered to patients with previously treated chronic lymphocytic leukemia (CLL).. <i>Journal of Clinical Oncology</i> , 2015, 33, 7012-7012.	0.8	3
233	Results of a phase III randomized, controlled study evaluating the efficacy and safety of idelalisib (IDELA) in combination with ofatumumab (OFA) for previously treated chronic lymphocytic leukemia (CLL).. <i>Journal of Clinical Oncology</i> , 2015, 33, 7023-7023.	0.8	12
234	Phase IIa study of single-agent MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL).. <i>Journal of Clinical Oncology</i> , 2015, 33, 8500-8500.	0.8	1

#	ARTICLE	IF	CITATIONS
235	The Role of the Slit-Robo Family in Adult Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 3816-3816.	0.6	0
236	Blockage of Wnt/B-Catenin Signaling By Nanoparticles Reduces Survival and Proliferation of CLL Cells in Vitro. <i>Blood</i> , 2015, 126, 3699-3699.	0.6	1
237	Angiopoietins in haematopoietic stem cell mobilisation in patients with haematological malignancies. <i>Blood Transfusion</i> , 2015, 13, 102-8.	0.3	3
238	Current and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art. <i>Expert Review of Hematology</i> , 2014, 7, 841-857.	1.0	15
239	The differences in thermal profiles between normal and leukemic cells exposed to anticancer drug evaluated by differential scanning calorimetry. <i>Journal of Thermal Analysis and Calorimetry</i> , 2014, 118, 1339-1344.	2.0	16
240	Expression of Toll-Like Receptors 3, 7, and 9 in Peripheral Blood Mononuclear Cells from Patients with Systemic Lupus Erythematosus. <i>Mediators of Inflammation</i> , 2014, 2014, 1-11.	1.4	56
241	Spontaneous <i>in vitro</i> apoptosis of <i>de novo</i> chronic lymphocytic leukemia cells correlates with risk of the disease progression. , 2014, 86, 410-417.		8
242	Long-term results of the Polish Adult Leukemia Group PALG-CLL2 phase III randomized study comparing cladribine-based combinations in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2014, 55, 606-610.	0.6	5
243	Clonal evolution in <i>CLL</i> patients as detected by <i>FISH</i> versus chromosome banding analysis, and its clinical significance. <i>European Journal of Haematology</i> , 2014, 92, 91-101.	1.1	20
244	A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2014, 167, 466-477.	1.2	30
245	Polymorphism of CD44 Influences the Efficacy of CD34+ Cells Mobilization in Patients with Hematological Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 986-991.	2.0	25
246	New horizons in the treatment of chronic lymphocytic leukemia. <i>Acta Haematologica Polonica</i> , 2014, 45, 122-131.	0.1	6
247	Spontaneous <i>in vitro</i> apoptosis of <i>de novo</i> chronic lymphocytic leukemia cells correlates with risk of the disease progression. , 2014, , n/a-n/a.		6
248	Current Phase II antibody-drug conjugates for the treatment of lymphoid malignancies. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 911-924.	1.9	17
249	Pro-apoptotic effect of an anti-CD37 scFv-Fc fusion protein, in combination with the anti-CD20 antibody, ofatumumab, on tumour cells from B-cell malignancies. <i>European Journal of Cancer</i> , 2014, 50, 2677-2684.	1.3	10
250	Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia. <i>New England Journal of Medicine</i> , 2014, 371, 213-223.	13.9	1,427
251	Rekomendacje diagnostyczne i terapeutyczne dla przewlekłej, białaczki limfocytowej w 2014 r. – raport Grupy Roboczej PTHiT oraz PALG – CLL. <i>Acta Haematologica Polonica</i> , 2014, 45, 221-239.	0.1	3
252	Cladribine in the treatment of acute myeloid leukemia. <i>Leukemia Research</i> , 2014, 38, 425-427.	0.4	12

#	ARTICLE	IF	CITATIONS
253	Anti-CD37 antibodies for chronic lymphocytic leukemia. Expert Opinion on Biological Therapy, 2014, 14, 651-661.	1.4	27
254	PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia. Blood, 2014, 124, 420-425.	0.6	14
255	Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma. Blood, 2014, 123, 4136-4142.	0.6	125
256	Cytotoxic activity of the amphibian ribonucleases onconase and r-amphinase on tumor cells from B cell lymphoproliferative disorders. International Journal of Oncology, 2014, 45, 419-425.	1.4	13
257	Efficacy and Safety of Frontline Bortezomib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) Vs R-CHOP in a Subset of Newly Diagnosed Mantle Cell Lymphoma (MCL) Patients (Pts) Medically Eligible for Transplantation in the Randomized Phase 3 LYM-3002 Study (NCT00722137). Blood, 2014, 124, 3064-3064.	0.6	5
258	Bortezomib (Btz) Dose Intensity Is the Strongest Predictor for Overall Survival (OS) in Mantle Cell Lymphoma (MCL) Patients (Pts) Not Considered for Transplantation, Receiving Frontline Btz Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) Therapy in the Phase 3 LYM-3002 Study. Blood, 2014, 124, 4412-4412.	0.6	2
259	Responses to Romidepsin in Patients with Cutaneous T-Cell Lymphoma (CTCL) and Prior Treatment with Systemic Chemotherapy: Subanalysis from the Pivotal Phase 2 Study. Blood, 2014, 124, 4451-4451.	0.6	2
260	Hematologic and Immunologic Function and Patient Well-Being for the Phase III RESONATE™ Study of Ibrutinib Vs Ofatumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Blood, 2014, 124, 4696-4696.	0.6	12
261	Phase 2 Study of Orlertuzumab (TRU-016), an Anti-CD37 ADAPTIR™ Protein, in Combination with Bendamustine Vs Bendamustine Alone in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL) - Updated Results. Blood, 2014, 124, 5642-5642.	0.6	4
262	Randomized phase 3 study of rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in newly diagnosed mantle cell lymphoma (MCL) patients (pts) ineligible for bone marrow transplantation (BMT).. Journal of Clinical Oncology, 2014, 32, 8500-8500.	0.8	9
263	A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated chronic lymphocytic leukemia (CLL).. Journal of Clinical Oncology, 2014, 32, TPS7127-TPS7127.	0.8	2
264	Cytotoxic and apoptosis-inducing effects of bendamustine used alone and in combination with rituximab on chronic lymphocytic leukemia cells in vitro. Postepy Higieny I Medycyny Doswiadczalnej, 2014, 68, 1433-1443.	0.1	3
265	New Therapies for Chronic Lymphocytic Leukemia. Current Cancer Therapy Reviews, 2014, 9, 245-257.	0.2	0
266	Human Leukocyte Antigen-G Polymorphisms Influence Clinical Outcome in Diffuse Large B-Cell Lymphoma. Blood, 2014, 124, 1643-1643.	0.6	0
267	HLA-G and MHC Class II Protein Expression in Diffuse Large B-Cell Lymphoma. Blood, 2014, 124, 1642-1642.	0.6	0
268	Final Overall Survival Results of a Randomized Trial Comparing Bortezomib Plus Pegylated Liposomal Doxorubicin with Bortezomib Alone in Subjects with Relapsed or Refractory Multiple Myeloma. Blood, 2014, 124, 3448-3448.	0.6	1
269	Cladribine Added to Daunorubicin and Cytarabine Induction Regimen Prolongs Survival of Patients with Complex but Not Monosomal Karyotype Acute Myeloid Leukemia – Retrospective Analysis of Polish Adult Leukemia Group (PALG). Blood, 2014, 124, 2347-2347.	0.6	0
270	A Phase IIa, Open-Label, Multicenter Study of Single-Agent MOR00208, an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma. Blood, 2014, 124, 3089-3089.	0.6	0

#	ARTICLE	IF	CITATIONS
271	Impact of Drug Transporters ABCB1 and ABCG2 and Regulators of Xenobiotic Transport and Metabolism Pxr and CAR Gene Polymorphisms on Clinical Efficacy of Imatinib in Chronic Myeloid Leukemia (CML). <i>Blood</i> , 2014, 124, 5222-5222.	0.6	0
272	Expression of Smad Proteins as a Potential Prognostic Factor in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2014, 124, 1957-1957.	0.6	3
273	BCR Signaling in Chronic Lymphocytic Leukemia and Related Inhibitors Currently in Clinical Studies. <i>International Reviews of Immunology</i> , 2013, 32, 358-376.	1.5	42
274	Polymorphisms of the glucocorticoid receptor gene: impact on clinical outcome of multiple myeloma. <i>Comparative Clinical Pathology</i> , 2013, 22, 157-163.	0.3	0
275	The kinetics and apoptotic profile of circulating endothelial cells in autologous hematopoietic stem cell transplantation in patients with lymphoproliferative disorders. <i>Annals of Hematology</i> , 2013, 92, 1255-1262.	0.8	9
276	Effects of Toll-like receptor 7 and Toll-like receptor 9 signaling stimulators and inhibitors on chronic lymphocytic leukemia cells ex vivo and their interactions with cladribine. <i>Leukemia and Lymphoma</i> , 2013, 54, 1268-1278.	0.6	12
277	Circulating endothelial cell kinetics and their potential predictive value during mobilization procedure. <i>Journal of Clinical Apheresis</i> , 2013, 28, 341-348.	0.7	4
278	Clinically meaningful reduction in pruritus in patients with cutaneous T-cell lymphoma treated with romidepsin. <i>Leukemia and Lymphoma</i> , 2013, 54, 284-289.	0.6	36
279	Polymorphisms of <i>TNF</i> and <i>IL10</i> genes and clinical outcome of patients with chronic lymphocytic leukemia. <i>Genes Chromosomes and Cancer</i> , 2013, 52, 287-296.	1.5	28
280	In vivo and ex vivo responses of CLL cells to purine analogs combined with alkylating agent. <i>Pharmacological Reports</i> , 2013, 65, 460-475.	1.5	4
281	Przewlekła, a białaczka limfocytowa u ludzi starszych. <i>Acta Haematologica Polonica</i> , 2013, 44, 93-98.	0.1	2
282	Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia. <i>Future Oncology</i> , 2013, 9, 69-91.	1.1	26
283	CD38 gene polymorphisms and genetic predisposition to multiple myeloma. <i>Acta Haematologica Polonica</i> , 2013, 44, 58-62.	0.1	1
284	Different prognosis of acute myeloid leukemia harboring monosomal karyotype with total or partial monosomies determined by FISH: Retrospective PALG study. <i>Leukemia Research</i> , 2013, 37, 293-299.	0.4	7
285	Older and new purine nucleoside analogs for patients with acute leukemias. <i>Cancer Treatment Reviews</i> , 2013, 39, 851-861.	3.4	78
286	The Influence of Maltotriose-Modified Poly(propylene imine) Dendrimers on the Chronic Lymphocytic Leukemia Cells <i>in Vitro</i> : Dense Shell G4 PPI. <i>Molecular Pharmaceutics</i> , 2013, 10, 2490-2501.	2.3	32
287	The emerging therapeutic role of antibody mixtures. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 953-958.	1.4	10
288	Immune thrombocytopenia in patients with chronic lymphocytic leukemia treated with cladribine-based regimens or chlorambucil – follow-up of PALG vs CLL randomized trials. <i>European Journal of Haematology</i> , 2013, 91, 1-9.	1.1	3

#	ARTICLE	IF	CITATIONS
289	Toward personalized therapy for chronic lymphocytic leukemia. <i>Cancer Biology and Therapy</i> , 2013, 14, 6-12.	1.5	6
290	Inactivation of TP53 correlates with disease progression and low miR-34a expression in previously treated chronic lymphocytic leukemia patients. <i>Blood</i> , 2013, 121, 3650-3657.	0.6	33
291	Maintenance in CLL. <i>Blood</i> , 2013, 122, 3854-3855.	0.6	10
292	Promising anti-leukemic activity of atorvastatin. <i>Oncology Reports</i> , 2013, 29, 2065-2071.	1.2	7
293	Plasmablastic Transformation of Low-grade B-cell Lymphomas. <i>American Journal of Surgical Pathology</i> , 2013, 37, 272-281.	2.1	59
294	Inhibitors of B-Cell Receptor Signaling for the Treatment of Chronic Lymphocytic Leukemia. <i>Journal of Leukemia (Los Angeles, Calif)</i> , 2013, 01, .	0.1	3
295	New Purine Nucleoside Analogs for Acute Lymphoblastic Leukemia. <i>Clinical Cancer Drugs</i> , 2013, 1, 2-10.	0.3	14
296	Real-Life Comparison Of Severe Vascular Events and Other Non-Hematological Complications In CML Patients Treated With Second Line Nilotinib Or Dasatinib. <i>Blood</i> , 2013, 122, 1491-1491.	0.6	3
297	A Randomized, Multicenter Study (PALG CLL4/ ML 21283) Of Maintenance Treatment With Rituximab Versus Observation After Induction Treatment With Rituximab, Cladribine, and Cyclophosphamide (RCC) Regimen In Patients With Progressive Chronic Lymphocytic Leukemia: Interim Analysis. <i>Blood</i> , 2013, 122, 1640-1640.	0.6	1
298	Phase 2 Study Of Otlertuzumab (TRU-016), An Anti-CD37 ADAPTIIR™ Protein, In Combination With Bendamustine Vs Bendamustine Alone In Patients With Relapsed Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2013, 122, 2860-2860.	0.6	5
299	Ofatumumab + Chlorambucil Versus Chlorambucil Alone In Patients With Untreated Chronic Lymphocytic Leukemia (CLL): Results Of The Phase III Study Complement 1 (OMB110911). <i>Blood</i> , 2013, 122, 528-528.	0.6	49
300	Mechanisms of action of the anti-VEGF monoclonal antibody bevacizumab on chronic lymphocytic leukemia cells. <i>Postepy Higieny I Medycyny Doswiadczalnej</i> , 2013, 67, 107-118.	0.1	11
301	In vitro cytotoxicity of ranpirnase (onconase) in combination with components of R-CHOP regimen against diffuse large B cell lymphoma (DLBCL) cell line. <i>Postepy Higieny I Medycyny Doswiadczalnej</i> , 2013, 67, 1166-1172.	0.1	11
302	New Monoclonal Antibodies for Indolent Non-Hodgkin Lymphoma. , 2013, , 191-212.		0
303	Polymorphism Of CD44 Influences Efficacy Of CD34+Cells Mobilization In Patients With Hematological Malignancies. <i>Blood</i> , 2013, 122, 3270-3270.	0.6	0
304	Polymorphisms Of Human Leukocyte Antigen-G Gene and Clinical Outcome Of Patients With Chronic Lymphocytic Leukemia. <i>Blood</i> , 2013, 122, 4151-4151.	0.6	1
305	Purine Analogues Based Induction Regimen Followed By Allo-HSCT Is An Effective Treatment Modality Of Philadelphia Chromosome-Positive Acute Myeloid Leukemia-Retrospective Analysis Of Polish Adult Leukemia Group (PALG). <i>Blood</i> , 2013, 122, 1461-1461.	0.6	0
306	Clinical Relevance Of VEGF-C/VEGF-D/VEGFR-3 Axis In Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2013, 122, 5060-5060.	0.6	0

#	ARTICLE	IF	CITATIONS
307	High Expression Of Cereblon (CRBN) Is Associated With Achievement Of Complete Response To Thalidomide Plus Fludarabine Regimen In Chronic Lymphocytic Leukemia. <i>Blood</i> , 2013, 122, 4934-4934.	0.6	0
308	Population Pharmacokinetics of Rituximab in Patients With Chronic Lymphocytic Leukemia. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 1918-1926.	1.0	65
309	Cladribine, But Not Fludarabine, Added to Daunorubicin and Cytarabine During Induction Prolongs Survival of Patients With Acute Myeloid Leukemia: A Multicenter, Randomized Phase III Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 2441-2448.	0.8	214
310	Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). <i>Blood</i> , 2012, 119, 1123-1129.	0.6	520
311	Pharmacokinetic evaluation and therapeutic activity of bendamustine in B-cell lymphoid malignancies. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2012, 8, 1455-1468.	1.5	12
312	The evaluation and optimal use of rituximab in lymphoid malignancies. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2012, , 1.	1.2	2
313	Editorial [Hot Topic: Novel and Emerging Drugs for Leukemias (Guest Editor: Tadeusz Robak)]. <i>Current Cancer Drug Targets</i> , 2012, 12, 453-457.	0.8	0
314	Purine Nucleoside Analogs in the Treatment of Rarer Chronic Lymphoid Leukemias. <i>Current Pharmaceutical Design</i> , 2012, 18, 3373-3388.	0.9	33
315	Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial. <i>Haematologica</i> , 2012, 97, 784-791.	1.7	49
316	Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia. <i>Blood</i> , 2012, 120, 3670-3676.	0.6	55
317	Serum Tumor Necrosis Factor- α and Interleukin-10 Levels as Markers to Predict Outcome of Patients with Chronic Lymphocytic Leukemia in Different Risk Groups Defined by the IGHV Mutation Status. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2012, 60, 477-486.	1.0	15
318	Przeciwciała monoklonalne w leczeniu przewlekłej białaczki limfocytowej. <i>Acta Haematologica Polonica</i> , 2012, 43, 99-106.	0.1	2
319	Zalecenia Polskiej Grupy Szpiczakowej dotyczące rozpoznawania i leczenia szpiczaka plazmocytowego na rok 2012. <i>Acta Haematologica Polonica</i> , 2012, 43, 7-47.	0.1	5
320	Rituximab for chronic lymphocytic leukemia. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 503-515.	1.4	21
321	Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia. <i>Journal of Clinical Oncology</i> , 2012, 30, 1822-1828.	0.8	287
322	Changes in the apoptotic gene expression profile in CLL patients treated with rituximab combined with cladribine and cyclophosphamide-preliminary results. <i>Leukemia Research</i> , 2012, 36, 1134-1140.	0.4	0
323	Apoptotic gene expression under influence of fludarabine and cladribine in chronic lymphocytic leukemia-microarray study. <i>Pharmacological Reports</i> , 2012, 64, 412-420.	1.5	5
324	Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 921-947.	1.9	72

#	ARTICLE	IF	CITATIONS
325	The value of rituximab for the treatment of fludarabine-refractory chronic lymphocytic leukemia: a systematic review and qualitative analysis of the literature. <i>Leukemia and Lymphoma</i> , 2012, 53, 820-829.	0.6	4
326	Poor prognosis of <sc>H</sc>odgkin variant of <sc>R</sc>ichter transformation in chronic lymphocytic leukemia treated with cladribine. <i>British Journal of Haematology</i> , 2012, 158, 286-288.	1.2	20
327	Nanoparticles – a Novel Approach to Chronic Lymphocytic Leukemia Treatment?. <i>Blood</i> , 2012, 120, 4601-4601.	0.6	5
328	Type of serum influences the rituximab dependent cytotoxicity and apoptosis of chronic lymphocytic leukemia cells in vitro. <i>Postępy Higieny i Medycyny Doswiadczalnej</i> , 2012, 66, 730-738.	0.1	5
329	Diverse Impact of Notch-1, Jagged-1 and Dll-1 Expression On Response to Treatment and Relapse Free Survival in Acute Myeloid Leukemia.. <i>Blood</i> , 2012, 120, 2520-2520.	0.6	0
330	Daunorubicine, Cytarabine and Cladribine (DAC) Vs Daunorubicine and Cytarabine (DA) Induction Treatment in Elderly Acute Myeloid Leukemia (AML) Patients – Results of the Prospective, Multicenter, Randomized Trial of the Polish Adult Leukemia Group (PALG). <i>Blood</i> , 2012, 120, 3602-3602.	0.6	0
331	Inhibitors of Apoptosis Proteins (IAPs) as Potential Molecular Targets for Therapy of Hematological Malignancies. <i>Current Molecular Medicine</i> , 2011, 11, 633-649.	0.6	76
332	New Anti-CD20 Monoclonal Antibodies for the Treatment of B-Cell Lymphoid Malignancies. <i>BioDrugs</i> , 2011, 25, 13-25.	2.2	96
333	Efficacy and Safety of Pegylated Liposomal Doxorubicin in Combination With Bortezomib for Multiple Myeloma: Effects of Adverse Prognostic Factors on Outcome. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 44-49.	0.2	38
334	Management of hairy cell leukemia variant. <i>Leukemia and Lymphoma</i> , 2011, 52, 53-56.	0.6	20
335	Hairy-cell leukemia variant: Recent view on diagnosis, biology and treatment. <i>Cancer Treatment Reviews</i> , 2011, 37, 3-10.	3.4	95
336	Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. <i>Lancet Oncology</i> , The, 2011, 12, 431-440.	5.1	835
337	New nucleoside analogs for patients with hematological malignancies. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 343-359.	1.9	32
338	Dasatinib in the Treatment of Chronic Myeloid Leukemia. <i>Current Signal Transduction Therapy</i> , 2011, 6, 99-105.	0.3	0
339	Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes and Myeloid Leukemia. <i>Current Cancer Drug Targets</i> , 2011, 11, 837-848.	0.8	21
340	Novel Systemic Drugs for Cutaneous T-Cell Lymphoma. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2011, 6, 70-93.	0.8	3
341	Chlorambucil for the treatment of patients with chronic lymphocytic leukaemia, or small lymphocytic lymphoma. <i>The Cochrane Library</i> , 2011, , .	1.5	1
342	Efficacy and safety of a nanofiltered liquid intravenous immunoglobulin product in patients with primary immunodeficiency and idiopathic thrombocytopenic purpura. <i>Vox Sanguinis</i> , 2011, 101, 138-146.	0.7	18

#	ARTICLE	IF	CITATIONS
343	Characterization of haematological parameters with bortezomibâ€“melphalanâ€“prednisone <i>versus</i> melphalanâ€“prednisone in newly diagnosed myeloma, with evaluation of longâ€“term outcomes and risk of thromboembolic events with use of erythropoiesisâ€“stimulating agents: analysis of the VISTA trial. <i>British Journal of Haematology</i> , 2011, 153, 212-221.	1.2	13
344	Common genetic variation at 15q25.2 impacts on chronic lymphocytic leukaemia risk. <i>British Journal of Haematology</i> , 2011, 154, 229-233.	1.2	19
345	Chromosomal aberrations in chronic lymphocytic leukemia detected by conventional cytogenetics with DSP30 as a single agent: Comparison with FISH. <i>Leukemia Research</i> , 2011, 35, 1032-1038.	0.4	17
346	Novel and Emerging Drugs for Acute Myeloid Leukemia: Pharmacology and Therapeutic Activity. <i>Current Medicinal Chemistry</i> , 2011, 18, 638-666.	1.2	25
347	Polymorphisms of Mir-34b/c, Mir-146a and Mir-196a-2 and Predisposition to Chronic Lymphocytic Leukemia and Monoclonal B-Cell Lymphocytosis. <i>Blood</i> , 2011, 118, 4585-4585.	0.6	3
348	Final Results From a Phase II Trial with the First in Class Recombinant Polyclonal Antibody Product Rozrolimupab in Primary Immune Thrombocytopenia. <i>Blood</i> , 2011, 118, 527-527.	0.6	3
349	Older and New Formulations of Cladribine: Pharmacology and Clinical Efficacy in Hematological Malignancies. , 2011, , 497-524.		0
350	Novel Purine Nucleoside Analogues for Hematological Malignancies. , 2011, , 219-240.		0
351	Is Type of Monosomy (Total or Partial) Crucial for Prognostic Value of Monosomal Karyotype in AML Patients? â€“ Preliminary Results of Retrospective Polish Adult Leukemia Group (PALG) Study,. <i>Blood</i> , 2011, 118, 3537-3537.	0.6	0
352	Disruption of TP53 function by Point Mutations and Deletions Is Associated with An Increased Risk of Disease Progression within Previously Treated, Relapsed Chronic Lymphocytic Leukemia Patients. <i>Blood</i> , 2011, 118, 2445-2445.	0.6	0
353	Pro-Apoptotic Effect of An Anti-CD37 Scfv-Fc Fusion Protein, in Combination with the Anti-CD20 Antibody, Ofatumumab, on Tumor Cells From B-Cell Malignancies. <i>Blood</i> , 2011, 118, 1662-1662.	0.6	0
354	Kinetics and Apoptotic Profile of Circulating Endothelial Cells In Patients Undergoing Autologous Stem Cell Transplantation. <i>Blood</i> , 2011, 118, 2961-2961.	0.6	1
355	Pro-Apoptotic Activity of Honokiol Analogues in B-Cell Lymphoid Malignancies. <i>Blood</i> , 2011, 118, 1663-1663.	0.6	18
356	Low Expression of MiR-34a in Previously Treated Chronic Lymphocytic Leukemia Patients Is Limited to Patients with a Complete Disruption of TP53 Function and Does Not Correlate with MDM2 SNP309,. <i>Blood</i> , 2011, 118, 3521-3521.	0.6	0
357	Detection of P53 mutations in different cancer types is improved by cDNA sequencing. <i>Oncology Letters</i> , 2010, 1, 717-721.	0.8	5
358	Effect of FCGR2A and FCGR3A variants on CLL outcome. <i>Blood</i> , 2010, 116, 4212-4222.	0.6	54
359	Plasma TNF-Î± and IL-10 Level-Based Prognostic Model Predicts Outcome of Patients with Diffuse Large B-Cell Lymphoma in Different Risk Groups Defined by the International Prognostic Index. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2010, 58, 131-141.	1.0	37
360	Circulating endothelial cells in essential thrombocythemia and polycythemia vera: correlation with JAK2-V617F mutational status, angiogenic factors and coagulation activation markers. <i>International Journal of Hematology</i> , 2010, 91, 792-798.	0.7	27

#	ARTICLE	IF	CITATIONS
361	Roscovitine (Seliciclib) affects CLL cells more strongly than combinations of fludarabine or cladribine with cyclophosphamide: Inhibition of CDK7 sensitizes leukemic cells to caspase-dependent apoptosis. <i>Journal of Cellular Biochemistry</i> , 2010, 109, 217-235.	1.2	19
362	Influence of high expression of Smac/DIABLO protein on the clinical outcome in acute myeloid leukemia patients. <i>Leukemia Research</i> , 2010, 34, 1308-1313.	0.4	26
363	Pharmacokinetics and pharmacokinetic/pharmacodynamic associations of ofatumumab, a human monoclonal CD20 antibody, in patients with relapsed or refractory chronic lymphocytic leukaemia: a phase 1² study. <i>British Journal of Haematology</i> , 2010, 150, 58-71.	1.2	37
364	APPLICATION OF NEW DRUGS IN CHRONIC LYMPHOCYTIC LEUKEMIA. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2010, 2, e2010011.	0.5	4
365	Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 1749-1755.	0.8	541
366	Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 1529-1543.	1.1	19
367	Efficacy and safety of a new intravenous immunoglobulin 10% formulation (octagam [®] 10%) in patients with immune thrombocytopenia. <i>Hematology</i> , 2010, 15, 351-359.	0.7	24
368	Comparison of Cladribine Plus Cyclophosphamide With Fludarabine Plus Cyclophosphamide As First-Line Therapy for Chronic Lymphocytic Leukemia: A Phase III Randomized Study by the Polish Adult Leukemia Group (PALG-CLL3 Study). <i>Journal of Clinical Oncology</i> , 2010, 28, 1863-1869.	0.8	86
369	Expression and prognostic significance of the inhibitor of apoptosis protein (IAP) family and its antagonists in chronic lymphocytic leukaemia. <i>European Journal of Cancer</i> , 2010, 46, 800-810.	1.3	59
370	Infectious complications in patients with acute myeloid leukemia treated according to the protocol with daunorubicin and cytarabine with or without addition of cladribine. A multicenter study by the Polish Adult Leukemia Group (PALG). <i>International Journal of Infectious Diseases</i> , 2010, 14, e132-e140.	1.5	33
371	Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 4485-4491.	0.8	604
372	Improving FCR immunochemotherapy in CLL. <i>Blood</i> , 2010, 115, 437-438.	0.6	14
373	Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 1756-1765.	0.8	437
374	Prognostic value of the bone marrow microvessel density in progressive B-cell chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2010, 51, 1351-1353.	0.6	6
375	Plasma levels of angiogenic factors and circulating endothelial cells in essential thrombocythemia: correlation with cytoreductive therapy and JAK2 ^{V617F} mutational status. <i>Leukemia and Lymphoma</i> , 2010, 51, 1-7.	0.6	16
376	A Phase 1 Study of Moxetumomab Pasudotox, An Anti-CD22 Recombinant Immunotoxin, In Relapsed/Refractory Hairy Cell Leukemia (HCL): Updated Results. <i>Blood</i> , 2010, 116, 2516-2516.	0.6	6
377	The Prognostic Role of Jagged-1 Protein Expression In Acute Myeloid Leukemia Patients. <i>Blood</i> , 2010, 116, 2726-2726.	0.6	1
378	A Phase 3 Prospective Randomized International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib In Patients with Relapsed Multiple Myeloma. <i>Blood</i> , 2010, 116, 312-312.	0.6	9

#	ARTICLE	IF	CITATIONS
379	Overall Survival Advantage and Acceptable Safety Profile with Fludarabine In Combination with Alemtuzumab (FluCam) In Previously Treated Patients with Advanced Stage Chronic Lymphocytic Leukemia. <i>Blood</i> , 2010, 116, 919-919.	0.6	3
380	Final Analysis From the International Trial of Single-Agent Ofatumumab In Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia. <i>Blood</i> , 2010, 116, 921-921.	0.6	9
381	Changes In Apoptotic Gene Expression Profile In CLL Patients Treated with Cladribine, Cyclophosphamide and Rituximab (CCR). <i>Blood</i> , 2010, 116, 2469-2469.	0.6	1
382	The TNF γ 308G>A Polymorphism Predicts Outcome of Patients with B-Cell Chronic Lymphocytic Leukemia In Relation to the IgVH Mutation Status. <i>Blood</i> , 2010, 116, 2421-2421.	0.6	0
383	Improved Outcome of Adult Acute Lymphoblastic Leukemia Treated with Individualized Protocol Adjusted to the Status of Minimal Residual Disease and Age. Interim Analysis of PALG ALL 5 th 2007 Study. <i>Blood</i> , 2010, 116, 2138-2138.	0.6	0
384	The Role of Inhibitor of Apoptosis Proteins Family Expression In Acute Myeloid Leukemia Patients. <i>Blood</i> , 2010, 116, 2728-2728.	0.6	0
385	Clinical Relevance of Vascular Endothelial Growth Factor Type A (VEGFA) and VEGF Receptor Type 2 (VEGFR2) Gene Polymorphism In Chronic Lymphocytic Leukemia. <i>Blood</i> , 2010, 116, 4467-4467.	0.6	0
386	Antitumor Activity of Amphibian Ribonucleases, Onconase and R-Amhinase, on Tumor Cells From B-Cell Lymphoproliferative Disorders. <i>Blood</i> , 2010, 116, 2842-2842.	0.6	0
387	Treatment of Elderly Patients with Acute Myeloid Leukemia Adjusted to Age, Performance Status, Organ Function and the Presence of Co-Morbidities. Final Results of the Polish Adult Leukemia Group (PALG) 1/2005 Study.. <i>Blood</i> , 2010, 116, 1067-1067.	0.6	0
388	Assessment of Minimal Residual Disease (MRD) In Relapsed CLL Patients Treated with Fludarabine and Cyclophosphamide with or without Rituximab (REACH). <i>Blood</i> , 2010, 116, 1390-1390.	0.6	0
389	A Review of the Management of Chronic Myeloid Leukemia with Dasatinib. <i>Clinical Medicine Therapeutics</i> , 2009, 1, CMT.S1167.	0.1	0
390	<i>CD38</i> Gene Polymorphisms Contribute to Genetic Susceptibility to B-Cell Chronic Lymphocytic Leukemia: Evidence from Two Case-Control Studies in Polish Caucasians. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 945-953.	1.1	32
391	Clofarabine as a Novel Nucleoside Analogue Approved to Treat Patients with Haematological Malignancies: Mechanism of Action and Clinical Activity. <i>Mini-Reviews in Medicinal Chemistry</i> , 2009, 9, 805-812.	1.1	21
392	Toll-Like Receptors and their Role in Hematologic Malignancies. <i>Current Molecular Medicine</i> , 2009, 9, 324-335.	0.6	27
393	Novel Drugs for Chronic Lymphoid Leukemias: Mechanism of Action and Therapeutic Activity. <i>Current Medicinal Chemistry</i> , 2009, 16, 2212-2234.	1.2	13
394	Current and emerging therapies for acute myeloid leukemia. <i>Clinical Therapeutics</i> , 2009, 31, 2349-2370.	1.1	129
395	Effect of Intracoronary Injection of Mononuclear Bone Marrow Stem Cells on Left Ventricular Function in Patients With Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2009, 104, 1336-1342.	0.7	67
396	Activity of cladribine combined with cyclophosphamide in frontline therapy for chronic lymphocytic leukemia with 17p13.1/TP53 deletion. <i>Cancer</i> , 2009, 115, 94-100.	2.0	26

#	ARTICLE	IF	CITATIONS
397	Impact of intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction on left ventricular perfusion and function: a 6-month follow-up gated ^{99m} Tc-MIBI single-photon emission computed tomography study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 587-593.	3.3	29
398	Roscovitine Triggers Apoptosis in B-Cell Chronic Lymphocytic Leukemia Cells with Similar Efficiency as Combinations of Conventional Purine Analogs with Cyclophosphamide. <i>Annals of the New York Academy of Sciences</i> , 2009, 1171, 124-131.	1.8	11
399	Polymorphisms and haplotypes in the multidrug resistance 1 gene (MDR1/ABCB1) and risk of multiple myeloma. <i>Leukemia Research</i> , 2009, 33, 332-335.	0.4	33
400	Calorimetric study as a potential test for choosing treatment of B-cell chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2009, 33, 308-314.	0.4	11
401	Toll-like receptors and their role in carcinogenesis and anti-tumor treatment. <i>Cellular and Molecular Biology Letters</i> , 2009, 14, 248-72.	2.7	58
402	Current and Emerging Treatments for Chronic Lymphocytic Leukaemia. <i>Drugs</i> , 2009, 69, 2415-2449.	4.9	39
403	Impact of granulocyte colony stimulating factor administered during induction and consolidation of adults with acute lymphoblastic leukemia on survival: long-term follow-up of the Polish adult leukemia group 4-96 study. <i>Leukemia and Lymphoma</i> , 2009, 50, 1050-1053.	0.6	2
404	Evaluation of circulating endothelial cells as noninvasive marker of angiogenesis in patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2009, 50, 62-67.	0.6	20
405	Elevated plasma levels of the angiogenic tetrapeptide acetyl-ser-asp-lys-pro are found in some patients with hematologic malignancies. <i>Leukemia and Lymphoma</i> , 2009, 50, 2096-2097.	0.6	8
406	The influence of low-dose aspirin and hydroxyurea on platelet-leukocyte interactions in patients with essential thrombocythemia. <i>Blood Coagulation and Fibrinolysis</i> , 2009, 20, 646-651.	0.5	8
407	Current Status of Older and New Purine Nucleoside Analogues in the Treatment of Lymphoproliferative Diseases. <i>Molecules</i> , 2009, 14, 1183-1226.	1.7	66
408	A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older. <i>Blood</i> , 2009, 114, 1166-1173.	0.6	129
409	Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse. <i>Blood</i> , 2009, 114, 4027-4033.	0.6	52
410	The Effect of Repeated Exposures to Low-Dose UV Radiation on the Apoptosis of Peripheral Blood Mononuclear Cells. <i>Archives of Dermatology</i> , 2009, 145, 133-8.	1.7	10
411	Monoclonal Antibodies in the Treatment of Systemic Lupus Erythematosus. <i>Current Drug Targets</i> , 2009, 10, 26-37.	1.0	32
412	Rapamycin, the mTOR kinase inhibitor, sensitizes acute myeloid leukemia cells, HL-60 cells, to the cytotoxic effect of arabinoside cytarabine. <i>Anti-Cancer Drugs</i> , 2009, 20, 693-701.	0.7	23
413	Quality-Adjusted Survival (Q-TWiST) Analysis of Patients with Relapsed or Refractory Chronic Lymphocytic Leukaemia Treated with Rituximab Plus Fludarabine and Cyclophosphamide (R-FC) Versus FC Alone.. <i>Blood</i> , 2009, 114, 1368-1368.	0.6	1
414	FC-Gamma Receptor (FCGR) 2A and 3A Polymorphisms Do Not Influence the Outcome of Relapsed or Refractory CLL Patients Treated with Rituximab, Fludarabine, and Cyclophosphamide (R-FC) or Fludarabine, and Cyclophosphamide (FC) Alone.. <i>Blood</i> , 2009, 114, 2338-2338.	0.6	1

#	ARTICLE	IF	CITATIONS
415	Correlation Between Serum Ofatumumab Concentrations, Baseline Patient Characteristics and Clinical Outcomes in Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Single-Agent Ofatumumab.. Blood, 2009, 114, 3433-3433.	0.6	7
416	Long-Term Health Outcomes and Costs Associated with the Use of Rituximab in Combination with fludarabine and Cyclophosphamide (R-FC) in the Treatment of relapsed or Refractory Chronic Lymphocytic Leukaemia (CLL) in Poland.. Blood, 2009, 114, 4528-4528.	0.6	1
417	Improved Progression-Free Survival (PFS) of Alemtuzumab (Campath® [®] , MabCampath® [®]) Plus Fludarabine (Fludara® [®]) Versus Fludarabine Alone as Second-Line Treatment of Patients with B-Cell Chronic Lymphocytic Leukemia: Preliminary Results From a Phase III Randomized Trial.. Blood, 2009, 114, 537-537.	0.6	5
418	Phase I Dose-Escalation Study of CAT-8015 (HA22), A CD22-Specific Targeted Immunotoxin, in Relapsed or Refractory Hairy Cell Leukemia.. Blood, 2009, 114, 888-888.	0.6	7
419	Ofatumumab for the treatment of chronic lymphocytic leukemia. Therapy: Open Access in Clinical Medicine, 2009, 6, 577-587.	0.2	1
420	Clinically Significant Responses Achieved with Romidepsin in 37 Patient with Cutaneous T-Cell Lymphoma (CTCL) with Blood Involvement.. Blood, 2009, 114, 2683-2683.	0.6	2
421	Cladribine in Combination with Standard Daunorubicine and Cytarabine (DAC) as a Remission Induction Treatment Improves the Overall Survival in Untreated Adults with AML Aged < 60 y Contrary to Combination Including Fludarabine (DAF): A Multicenter, Randomized, Phase III PALG AML 1/2004 DAC/DAF/DA Study in 673 Patients-A Final Update.. Blood, 2009, 114, 2055-2055.	0.6	1
422	Osteopontin - A New Angiogenic Factor Which Correlates with Circulating Endothelial Cells in Acute Myeloid Leukemia.. Blood, 2009, 114, 1004-1004.	0.6	0
423	The Prognostic Role of Smac/DIABLO Protein Expression in Acute Myeloid Leukemia.. Blood, 2009, 114, 2626-2626.	0.6	0
424	GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies. Current Opinion in Investigational Drugs, 2009, 10, 588-96.	2.3	52
425	TRU-016, a humanized anti-CD37 IgG fusion protein for the potential treatment of B-cell malignancies. Current Opinion in Investigational Drugs, 2009, 10, 1383-90.	2.3	35
426	Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-CSF) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group. European Journal of Haematology, 2008, 80, 115-126.	1.1	122
427	Kinetics and apoptotic profile of circulating endothelial cells as prognostic factors for induction treatment failure in newly diagnosed acute myeloid leukemia patients. Annals of Hematology, 2008, 87, 97-106.	0.8	24
428	Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy. Cancer, 2008, 112, 1529-1537.	2.0	68
429	Randomized comparison of cladribine alone or in combination with cyclophosphamide, and cyclophosphamide, vincristine and prednisone in previously untreated low-grade B-cell non-Hodgkin lymphoma patients. Cancer, 2008, 113, 367-375.	2.0	22
430	Treatment of chronic lymphoid leukemias with monoclonal antibodies: current place and perspectives. Drug Development Research, 2008, 69, 373-387.	1.4	3
431	Do polymorphisms in ABC transporter genes influence risk of childhood acute lymphoblastic leukemia?. Leukemia Research, 2008, 32, 1173-1175.	0.4	10
432	Pegylated Liposomal Doxorubicin plus Bortezomib in Relapsed or Refractory Multiple Myeloma: Efficacy and Safety in Patients with Renal Function Impairment. Clinical Lymphoma and Myeloma, 2008, 8, 352-355.	1.4	54

#	ARTICLE	IF	CITATIONS
433	Alemtuzumab for B-cell chronic lymphocytic leukemia. Expert Review of Anticancer Therapy, 2008, 8, 1033-1051.	1.1	30
434	Targeted Drugs in Chronic Myeloid Leukemia. Current Medicinal Chemistry, 2008, 15, 3036-3051.	1.2	60
435	The role of non-steroidal anti-inflammatory drugs in the risk of development and treatment of hematologic malignancies. Leukemia and Lymphoma, 2008, 49, 1452-1462.	0.6	29
436	Novel Monoclonal Antibodies for the Treatment of Chronic Lymphocytic Leukemia. Current Cancer Drug Targets, 2008, 8, 156-171.	0.8	32
437	Emerging drugs for rarer chronic lymphoid leukemias. Expert Opinion on Emerging Drugs, 2008, 13, 95-118.	1.0	0
438	Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood, 2008, 111, 1094-1100.	0.6	369
439	First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood, 2008, 111, 5486-5495.	0.6	247
440	New Therapies for Patients with Chronic Lymphocytic Leukemia. Current Cancer Therapy Reviews, 2008, 4, 235-242.	0.2	0
441	Addition of Cladribine to the Standard Daunorubicine - Cytarabine (DA 3+7) Remission Induction Protocol (DAC) Contrary to Adjunct of Fludarabine (DAF) Improves the Overall Survival in Untreated Adults with Acute Myeloid Leukemia Aged up to 60 Y: A Multicenter, Randomized, Phase III PALG AML 1/2004 DAF/DAC/DA Study in 673 Patients. Blood, 2008, 112, 133-133.	0.6	3
442	Erythropoiesis-Stimulating Agents Do Not Adversely Affect Long-Term Outcomes Nor Increase the Risk of Thromboembolic Events in Multiple Myeloma Patients Treated in the Phase III VISTA Trial.. Blood, 2008, 112, 1741-1741.	0.6	4
443	Randomized Comparison of Cladribine Plus Cyclophosphamide with Fludarabine Plus Cyclophosphamide in Untreated Patients with Chronic Lymphocytic Leukemia: Report of the Polish Adult Leukemia Group (PALG-CLL3).. Blood, 2008, 112, 2103-2103.	0.6	1
444	Clinically Significant Responses Achieved with Romidepsin in Treatment-Refractory Cutaneous T-Cell Lymphoma: Final Results from a Phase 2B, International, Multicenter, Registration Study. Blood, 2008, 112, 263-263.	0.6	8
445	Ofatumumab (HuMax-CD20), a Novel CD20 Monoclonal Antibody, Is An Active Treatment for Patients with CLL Refractory to Both Fludarabine and Alemtuzumab or Bulky Fludarabine-Refractory Disease: Results from the Planned Interim Analysis of An International Pivotal Trial. Blood, 2008, 112, 328-328.	0.6	31
446	Ex Vivo Cytotoxic Activity of Endoribonucleases, Onconase (ranpirnase) and R-Amphinase, against Acute Myeloblastic Leukemia Cells. Blood, 2008, 112, 4010-4010.	0.6	1
447	Rituximab, Fludarabine, and Cyclophosphamide (R-FC) Prolongs Progression Free Survival in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Compared with FC Alone: Final Results from the International Randomized Phase III REACH Trial. Blood, 2008, 112, 1ba-1ba-1.	0.6	38
448	Novel Purine Nucleoside Analogues for Hematological Malignancies. Recent Patents on Anti-Cancer Drug Discovery, 2008, 3, 123-136.	0.8	23
449	Polymorphisms in CD31/PECAM-1 and CD38 Genes Are Associated with Susceptibility to Multiple Myeloma. Blood, 2008, 112, 5113-5113.	0.6	0
450	Autoimmune Cytopenias in Patients with Chronic Lymphocytic Leukemia Treated with Cladribine. Blood, 2008, 112, 4179-4179.	0.6	0

#	ARTICLE	IF	CITATIONS
451	Activity of Anti-Tumor Endoribonucleases, Onconase (ranpirnase) and R-Amphinase in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2008, 112, 4205-4205.	0.6	1
452	Palifermin Does Not Influence the Incidence and Severity of GvHD Nor Long-Term Survival of Patients with Hematological Diseases Undergoing HSCT. <i>Blood</i> , 2008, 112, 4301-4301.	0.6	0
453	Expression and Prognostic Significance of the Inhibitor of Apoptosis Protein (IAPs) Family and Its Antagonists in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2008, 112, 360-360.	0.6	0
454	High Serum Level of Placental Growth Factor (PlGF) Predicts Adverse Overall Survival in Patients with Acute Myeloid Leukemia Treated with Standard Chemotherapy. <i>Blood</i> , 2008, 112, 3972-3972.	0.6	0
455	Impact of Interleukin-10 Gene Promoter Polymorphisms on Clinical Course of Chronic Lymphocytic Leukemia. <i>Blood</i> , 2008, 112, 4168-4168.	0.6	0
456	Ofatumumab, a human monoclonal antibody for lymphoid malignancies and autoimmune disorders. <i>Current Opinion in Molecular Therapeutics</i> , 2008, 10, 294-309.	2.8	33
457	Alemtuzumab Compared With Chlorambucil As First-Line Therapy for Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2007, 25, 5616-5623.	0.8	533
458	Forodesine (BCX-1777, Immucillin H) - A New Purine Nucleoside Analogue: Mechanism of Action and Potential Clinical Application. <i>Mini-Reviews in Medicinal Chemistry</i> , 2007, 7, 976-983.	1.1	34
459	Depsipeptide (FK228) as a Novel Histone Deacetylase Inhibitor: Mechanism of Action and Anticancer Activity. <i>Mini-Reviews in Medicinal Chemistry</i> , 2007, 7, 1062-1069.	1.1	27
460	Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression. <i>Journal of Clinical Oncology</i> , 2007, 25, 3892-3901.	0.8	607
461	Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial. <i>Blood</i> , 2007, 109, 3672-3675.	0.6	70
462	Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. <i>Blood</i> , 2007, 109, 5143-5150.	0.6	356
463	Recent progress in the management of chronic lymphocytic leukemia. <i>Cancer Treatment Reviews</i> , 2007, 33, 710-728.	3.4	32
464	Influence of cladribine alone and in combination with cyclophosphamide or cyclophosphamide and mitoxantrone on bone marrow angiogenesis in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2007, 48, 1042-1044.	0.6	5
465	Skin lesions in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2007, 48, 855-865.	0.6	152
466	Cladribine combined with cyclophosphamide and mitoxantrone is an active salvage therapy in advanced non-Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , 2007, 48, 1092-1101.	0.6	10
467	Human leukocyte antigens HLA DRB1 influence clinical outcome of chronic lymphocytic leukemia. <i>Haematologica</i> , 2007, 92, 710-711.	1.7	12
468	The influence of palifermin (Kepivance) on oral mucositis and acute graft versus host disease in patients with hematological diseases undergoing hematopoietic stem cell transplant. <i>Bone Marrow Transplantation</i> , 2007, 40, 983-988.	1.3	54

#	ARTICLE	IF	CITATIONS
469	Primary cutaneous marginal zone B-cell lymphoma in a patient with chronic lymphocytic leukaemia. <i>British Journal of Dermatology</i> , 2007, 157, 591-595.	1.4	11
470	Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia. <i>European Journal of Haematology</i> , 2007, 79, 107-113.	1.1	48
471	Romidepsin (depsipeptide) Induces Clinically Significant Responses in Treatment-Refractory CTCL: An International, Multicenter Study.. <i>Blood</i> , 2007, 110, 123-123.	0.6	6
472	Early Normalization of Serum Free Light Chain Is Associated with Prolonged Time to Progression Following Bortezomib ± Pegylated Liposomal Doxorubicin Treatment of Relapsed/Refractory Multiple Myeloma.. <i>Blood</i> , 2007, 110, 2735-2735.	0.6	1
473	The Prolonged Time to Progression with Pegylated Liposomal Doxorubicin + Bortezomib Versus Bortezomib Alone in Relapsed or Refractory Multiple Myeloma Is Unaffected by Extent of Prior Therapy or Previous Anthracycline Exposure.. <i>Blood</i> , 2007, 110, 410-410.	0.6	6
474	Circulating proangiogenic molecules PIGF, SDF-1 and sVCAM-1 in patients with systemic lupus erythematosus. <i>European Cytokine Network</i> , 2007, 18, 181-7.	1.1	25
475	Effect of Disease Stage and Time Since Diagnosis on Time to Progression for Pegylated Liposomal Doxorubicin + Bortezomib vs Bortezomib Alone in Relapsed or Refractory Multiple Myeloma.. <i>Blood</i> , 2007, 110, 2740-2740.	0.6	1
476	The Reduction of Leukemic Blasts in Bone Marrow Aspirate on Day 6 of Remission Induction Treatment Is Predictive for Complete Remission Rate and Survival in Adult Acute Myeloid Leukemia; the Results of Multicenter, Prospective Polish Adult Leukemia Group Trial.. <i>Blood</i> , 2007, 110, 4375-4375.	0.6	0
477	CD38 Gene Polymorphisms Contribute to Genetic Predisposition to B-Cell Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2007, 110, 491-491.	0.6	1
478	Influence of High Expression of p73 and p53 Proteins on Clinical Outcome in Acute Myeloid Leukemia Patients.. <i>Blood</i> , 2007, 110, 4306-4306.	0.6	0
479	Circulating Endothelial Cells as Noninvasive Marker of Angiogenesis in Patients with Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2007, 110, 1124-1124.	0.6	0
480	Efficacy and Safety of a New Intravenous Immunoglobulin Product in Patients with Chronic Immune Thrombocytopenic Purpura.. <i>Blood</i> , 2007, 110, 1307-1307.	0.6	1
481	Current treatment options in prolymphocytic leukemia. <i>Medical Science Monitor</i> , 2007, 13, RA69-80.	0.5	24
482	High activity of rituximab combined with cladribine and cyclophosphamide in a patient with pulmonary lymphomatoid granulomatosis and bone marrow involvement. <i>Leukemia and Lymphoma</i> , 2006, 47, 1667-1669.	0.6	14
483	Cytotoxic effect of R-etodolac (SDX-101) in combination with purine analogs or monoclonal antibodies on ex vivo B-cell chronic lymphocytic leukemia cells. <i>Leukemia and Lymphoma</i> , 2006, 47, 2625-2634.	0.6	13
484	Current treatment options in hairy cell leukemia and hairy cell leukemia variant. <i>Cancer Treatment Reviews</i> , 2006, 32, 365-376.	3.4	74
485	Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2). <i>Blood</i> , 2006, 108, 473-479.	0.6	119
486	Recent Clinical Trials of Cladribine in Hematological Malignancies and Autoimmune Disorders. <i>Reviews on Recent Clinical Trials</i> , 2006, 1, 15-34.	0.4	15

#	ARTICLE	IF	CITATIONS
487	Older and New Formulations of Cladribine. Pharmacology and Clinical Efficacy in Hematological Malignancies. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2006, 1, 23-38.	0.8	10
488	No Influence of 3435C>T ABCB1 (MDR1) Gene Polymorphism on Risk of Adult Acute Myeloid Leukemia and P-glycoprotein Expression in Blast Cells. <i>Therapeutic Drug Monitoring</i> , 2006, 28, 707-711.	1.0	23
489	Additive cytotoxic effect of bortezomib in combination with anti-CD20 or anti-CD52 monoclonal antibodies on chronic lymphocytic leukemia cells. <i>Leukemia Research</i> , 2006, 30, 1521-1529.	0.4	26
490	Peripheral blood lymphocyte apoptosis and circulating dendritic cells in patients with systemic lupus erythematosus: correlation with immunological status and disease-related symptoms. <i>Clinical Rheumatology</i> , 2006, 25, 225-233.	1.0	24
491	Interaction of doxorubicin and idarubicin with red blood cells from acute myeloid leukaemia patients. <i>Cell Biology International</i> , 2006, 30, 127-132.	1.4	23
492	New agents in chronic lymphocytic leukemia. <i>Current Treatment Options in Oncology</i> , 2006, 7, 200-212.	1.3	10
493	Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma. <i>Cancer</i> , 2006, 107, 1542-1550.	2.0	50
494	In vitro sensitivity of B-cell chronic lymphocytic leukemia to cladribine and its combinations with mafosfamide and/or mitoxantrone. <i>Oncology Reports</i> , 2006, 16, 1389.	1.2	9
495	Purine Nucleoside Analogs as Immunosuppressive and Antineoplastic Agents: Mechanism of Action and Clinical Activity. <i>Current Medicinal Chemistry</i> , 2006, 13, 3165-3189.	1.2	138
496	Circulating Total and Active Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinases-1 in Patients with Systemic Lupus Erythomatosus. <i>Mediators of Inflammation</i> , 2006, 2006, 1-7.	1.4	37
497	Incidence of Genomic Aberrations and Associated Efficacy from a Phase III Study Comparing Alemtuzumab (CAMPATHÂ®, MABCAMPATHÂ®) vs Chlorambucil as First Line Therapy for B-Cell Chronic Lymphocytic Leukemia (BCLL).. <i>Blood</i> , 2006, 108, 2092-2092.	0.6	4
498	Cladribine in Weekly Versus Daily Schedule for Untreated Active Hairy Cell Leukemia: Final Report of Polish Adult Leukemia Group (PALG) Prospective, Randomized, Multicenter Trial.. <i>Blood</i> , 2006, 108, 2485-2485.	0.6	6
499	Alemtuzumab (CAMPATHÂ®, MABCAMPATHÂ®) Has Superior Progression Free Survival (PFS) vs Chlorambucil as Front-Line Therapy for Patients with Progressive B-Cell Chronic Lymphocytic Leukemia (BCLL).. <i>Blood</i> , 2006, 108, 301-301.	0.6	7
500	Improved Survival in Acute Myeloid Leukaemia Patients Aged over 40 Given Cladribine in Combination with Standard Remission Induction (DA 3+7) and Consolidation Treatment (HD AraC). Seven Year Follow-Up of Prospective, Cooperative PALG Study.. <i>Blood</i> , 2006, 108, 2003-2003.	0.6	0
501	Deficiency of Blood Dendritic Cells in Patients with Multiple Myeloma: Possible Significance for Prediction of Response to First Line Treatment.. <i>Blood</i> , 2006, 108, 5032-5032.	0.6	0
502	Randomized Comparison of Cladribine Plus Cyclophosphamide with Fludarabine Plus Cyclophosphamide in Progressive Chronic Lymphocytic Leukemia: An Updated Report of Prospective PALG-CLL3 Study.. <i>Blood</i> , 2006, 108, 2826-2826.	0.6	1
503	Pharmacogenetics of Response to Glucocorticosteroids in Adults with Acute Lymphoblastic Leukemia.. <i>Blood</i> , 2006, 108, 2609-2609.	0.6	0
504	Elevated IL-10 plasma levels correlate with poor prognosis in diffuse large B-cell lymphoma. <i>European Cytokine Network</i> , 2006, 17, 60-6.	1.1	53

#	ARTICLE	IF	CITATIONS
505	In vitro sensitivity of B-cell chronic lymphocytic leukemia to cladribine and its combinations with mafosfamide and/or mitoxantrone. <i>Oncology Reports</i> , 2006, 16, 1389-95.	1.2	17
506	Lack of effect of repeated suberythematous ultraviolet-B exposures on human blood dendritic subtypes. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2005, 21, 249-253.	0.7	4
507	In vitro cytotoxic effect of proteasome inhibitor bortezomib in combination with purine nucleoside analogues on chronic lymphocytic leukaemia cells. <i>European Journal of Haematology</i> , 2005, 74, 407-417.	1.1	38
508	Circulating endothelial cells in patients with acute myeloid leukemia. <i>European Journal of Haematology</i> , 2005, 75, 492-497.	1.1	47
509	The place of cladribine in the treatment of chronic lymphocytic leukemia: a 10-year experience in Poland. <i>Annals of Hematology</i> , 2005, 84, 63-70.	0.8	6
510	Merkel cell carcinoma in a patient with B-cell chronic lymphocytic leukemia treated with cladribine and rituximab. <i>Leukemia and Lymphoma</i> , 2005, 46, 909-914.	0.6	39
511	Proapoptotic activity of alemtuzumab alone and in combination with rituximab or purine nucleoside analogues in chronic lymphocytic leukemia cells. <i>Leukemia and Lymphoma</i> , 2005, 46, 87-100.	0.6	46
512	Changes in leukemic cell nuclei revealed by differential scanning calorimetry. <i>Leukemia and Lymphoma</i> , 2005, 46, 121-128.	0.6	8
513	Alemtuzumab in the Treatment of Chronic Lymphocytic Leukemia. <i>BioDrugs</i> , 2005, 19, 9-22.	2.2	30
514	Therapy of chronic lymphocytic leukemia with purine analogs and monoclonal antibodies. <i>Transfusion and Apheresis Science</i> , 2005, 32, 33-44.	0.5	21
515	Therapy of Chronic Lymphocytic Leukaemia with Purine Nucleoside Analogues. <i>Drugs and Aging</i> , 2005, 22, 983-1012.	1.3	27
516	Rituximab Plus Purine Nucleoside Analogs in the Treatment of Indolent Lymphoid Malignancies. <i>American Journal of Cancer</i> , 2005, 4, 279-292.	0.4	4
517	Pharmacogenetic Analysis of Polymorphisms in Pharmacological Pathway of Vincristine, Doxorubicine and Dexamethasone (VAD Regimen) To Predict Response in Patients with Multiple Myeloma.. <i>Blood</i> , 2005, 106, 104-104.	0.6	1
518	The VH3-21 Gene Status Correlates with Elevated β_2 -Microglobulin Serum Levels and Shorter Overall Survival of Patients with Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2005, 106, 4988-4988.	0.6	0
519	Randomized Comparison of Cladribine Containing Regimens and COP in Previously Untreated Patients with Small Lymphocytic, Marginal Zone and Follicular Lymphoma.. <i>Blood</i> , 2005, 106, 4739-4739.	0.6	0
520	Anti-CD20 and Anti-CD52 Monoclonal Antibodies Enhance Cytotoxicity of Bortezomib Against Chronic Lymphocytic Leukemia Cells.. <i>Blood</i> , 2005, 106, 2972-2972.	0.6	0
521	Inhibition of mTOR Kinase Pathway Selectively Sensitizes Acute Myeloid Leukemia Cells to Cytarabine-Induced Apoptosis.. <i>Blood</i> , 2005, 106, 2474-2474.	0.6	0
522	Prospective, Randomized, Multicenter Phase III, Polish Adult Leukemia Group (PALG) Study Comparing DAF (DNR+AraC+Fludarabine), DAC (DNR+AraC+Cladribine), and Standard DA Regimen in Induction of Untreated Acute Myeloid Leukemia Patients - First Report.. <i>Blood</i> , 2005, 106, 4616-4616.	0.6	0

#	ARTICLE	IF	CITATIONS
523	Cytotoxic Effect of R-Etodolac (SDX-101) in Combination with Purine Analogues or Monoclonal Antibodies on Ex-Vivo B-Cell Chronic Lymphocytic Leukemia Cells.. Blood, 2005, 106, 2122-2122.	0.6	0
524	Circulating vascular endothelial growth factor (VEGF) and its soluble receptors in patients with chronic lymphocytic leukemia. European Cytokine Network, 2005, 16, 41-6.	1.1	24
525	The effect of subsequent therapies in patients with chronic lymphocytic leukemia previously treated with prednisone and either cladribine or chlorambucil. Haematologica, 2005, 90, 994-6.	1.7	9
526	Comparison of cladribine plus prednisone with chlorambucil plus prednisone in patients with chronic lymphocytic leukemia. Final report of the Polish Adult Leukemia Group (PALG CLL1). Medical Science Monitor, 2005, 11, PI71-9.	0.5	10
527	The mammalian target of the rapamycin (mTOR) kinase pathway: its role in tumourigenesis and targeted antitumour therapy. Cellular and Molecular Biology Letters, 2005, 10, 479-98.	2.7	80
528	Rituximab Followed by Cladribine in the Treatment of Heavily Pretreated Patients with Indolent Lymphoid Malignancies. Leukemia and Lymphoma, 2004, 45, 937-944.	0.6	29
529	Outcome and prognostic factors in advanced Hodgkin's disease treated with high-dose chemotherapy and autologous stem cell transplantation: a study of 341 patients. Annals of Oncology, 2004, 15, 1222-1230.	0.6	46
530	Second Malignancies and Richter's Syndrome in Patients with Chronic Lymphocytic Leukemia. Hematology, 2004, 9, 387-400.	0.7	49
531	An evaluation of factors predicting long-term response to thalidomide in 234 patients with relapsed or resistant multiple myeloma. British Journal of Cancer, 2004, 91, 1873-1879.	2.9	13
532	Richter's Syndrome in the Brain First Manifested as an Ischaemic Stroke. Leukemia and Lymphoma, 2004, 45, 1261-1267.	0.6	13
533	Clinical significance of circulating dendritic cells in patients with systemic lupus erythematosus. Mediators of Inflammation, 2004, 13, 171-180.	1.4	26
534	Exposure to Low Doses of Solar-Simulated Radiation Induces an Increase in the Myeloid Subtype of Blood Dendritic Cells. Scandinavian Journal of Immunology, 2004, 60, 429-435.	1.3	11
535	Treatment for primary refractory Hodgkin's disease: a comparison of high-dose chemotherapy followed by ASCT with conventional therapy. Bone Marrow Transplantation, 2004, 33, 1225-1229.	1.3	24
536	Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. European Journal of Haematology, 2004, 72, 314-321.	1.1	172
537	The influence of farnesyl protein transferase inhibitor R115777 (Zarnestra) alone and in combination with purine nucleoside analogs on acute myeloid leukemia progenitors in vitro. European Journal of Haematology, 2004, 73, 418-426.	1.1	18
538	Monoclonal antibodies in the treatment of autoimmune cytopenias. European Journal of Haematology, 2004, 72, 79-88.	1.1	78
539	2-Chlorodeoxyadenosine alone and in combination with cyclophosphamide and mitoxantrone induce apoptosis in B chronic lymphocytic leukemia cells in vivo. Cancer Detection and Prevention, 2004, 28, 433-442.	2.1	9
540	Monoclonal Antibodies in the Treatment of Chronic Lymphoid Leukemias. Leukemia and Lymphoma, 2004, 45, 205-219.	0.6	52

#	ARTICLE	IF	CITATIONS
541	Influence of 2-chlorodeoxyadenosine (cladribine) on human erythrocytes. International Journal of Biochemistry and Cell Biology, 2004, 36, 1645-1654.	1.2	8
542	Preliminary Safety and Efficacy Report of a Randomized Trial of Alemtuzumab vs Chlorambucil as Front-Line Therapy in 297 Patients with Progressive B-Cell Chronic Lymphocytic Leukemia.. Blood, 2004, 104, 2505-2505.	0.6	7
543	Randomized Multicenter Trial of Cladribine Alone (C) or in Combination with Cyclophosphamide (CC), and COP in Previously Untreated Low Grade B-Cell Non-Hodgkin Lymphoma Patients: The First Interim Analysis.. Blood, 2004, 104, 3305-3305.	0.6	9
544	Cladribine Alone or in Combination with Cyclophosphamide or Cyclophosphamide and Mitoxantrone as First Line Treatment in Chronic Lymphocytic Leukemia: An Early Report of Prospective Randomized Study.. Blood, 2004, 104, 337-337.	0.6	4
545	Randomized Comparison of Weekly Administration and Daily Courses of Cladribine in Patients with Hairy Cell Leukemia - Updated Results.. Blood, 2004, 104, 3478-3478.	0.6	3
546	Rapamycin, Inhibitor of Mtor Kinase, Sensitizes Leukemia Cells to Fludarabine-Induced Apoptosis, but Protects Survival of Normal Lymphocytes.. Blood, 2004, 104, 4497-4497.	0.6	2
547	The Effect of Subsequent Therapies in the Patients with Chronic Lymphocytic Leukemia Previously Treated with Cladribine and Prednisone or Chlorambucil and Prednisone in Randomized Studies.. Blood, 2004, 104, 4819-4819.	0.6	0
548	Addition of Cladribine to the Standard AML Treatment Improves Long-Term Outcome in High Tumor Burden and Older Than 40 Years Acute Myeloid Leukemia Patients. Five-Year Follow-Up of the Polish Adult Leukemia Group (PALG 1999 DAC vs. DA Study).. Blood, 2004, 104, 1795-1795.	0.6	1
549	An Open Label, Multi Center Study on the Efficacy and Safety of a Liquid, Ready-to-Use Intravenously Administered Anti-D Immunoglobulin in Patients with Chronic Immune Thrombocytopenic Purpura.. Blood, 2004, 104, 3943-3943.	0.6	12
550	Cytotoxic Effect of Proteasome Inhibitor Bortezomib in Combination with Purine Nucleoside Analogues on Chronic Lymphocytic Leukemia Cells in Vitro.. Blood, 2004, 104, 4822-4822.	0.6	1
551	Analysis of Common Single Nucleotide Polymorphisms in MDR1 Gene in Patients with Multiple Myeloma.. Blood, 2004, 104, 4371-4371.	0.6	0
552	Addition of Purine Analogues to Induction/Consolidation Regimen Does Not Impair Peripheral Blood Stem Cell Mobilization and Bone Marrow Harvest for Autotransplantation in Acute Myeloid Leukemia.. Blood, 2004, 104, 5198-5198.	0.6	0
553	Determination of the in vivo effects of cladribine alone and its combination with cyclophosphamide or cyclophosphamide and mitoxantrone on Bax and Bcl-2 protein expression in B-CLL cells. Oncology Reports, 2004, 11, 699-705.	1.2	3
554	The distribution of peripheral blood dendritic cells assayed by a new panel of anti-BDCA monoclonal antibodies in healthy representatives of the polish population. Cellular and Molecular Biology Letters, 2004, 9, 497-509.	2.7	28
555	Caspase-mediated Cell Death in Hematological Malignancies: Theoretical Considerations, Methods of Assessment, and Clinical Implications. Leukemia and Lymphoma, 2003, 44, 1089-1104.	0.6	22
556	Purine Nucleoside Analogues in the Treatment of Myleoid Leukemias. Leukemia and Lymphoma, 2003, 44, 391-409.	0.6	69
557	Hodgkin's Type of Richter's Syndrome in Familial Chronic Lymphocytic Leukemia Treated with Cladribine and Cyclophosphamide. Leukemia and Lymphoma, 2003, 44, 859-866.	0.6	22
558	Coexistence of Chronic Lymphocytic Leukemia and Essential Thrombocythemia. Leukemia and Lymphoma, 2003, 44, 1425-1431.	0.6	11

#	ARTICLE	IF	CITATIONS
559	The Influence of Imatinib Mesylate (STI571) used alone or in Combination with Purine Nucleoside Analogues on the Normal and Chronic Myelogenous Leukaemia Progenitor Cells<i>In Vitro</i>. Leukemia and Lymphoma, 2003, 44, 1549-1555.	0.6	10
560	Circulating proangiogenic cytokines and angiogenesis inhibitor endostatin in untreated patients with chronic lymphocytic leukemia. Mediators of Inflammation, 2003, 12, 167-171.	1.4	21
561	Vascular endothelial growth factor and its soluble receptors VEGFR-1 and VEGFR-2 in the serum of patients with systemic lupus erythematosus. Mediators of Inflammation, 2003, 12, 293-298.	1.4	58
562	The Influence of Imatinib Mesylate (STI571) used alone or in Combination with Purine Nucleoside Analogues on the Normal and Chronic Myelogenous Leukaemia Progenitor Cells In Vitro. Leukemia and Lymphoma, 2003, 44, 1549-1555.	0.6	6
563	Circulating angiogenic cytokines in multiple myeloma and related disorders. European Cytokine Network, 2003, 14, 40-51.	1.1	21
564	Efficacy and toxicity of low-dose melphalan in myelodysplastic syndromes and acute myeloid leukemia with multilineage dysplasia. Neoplasma, 2003, 50, 172-5.	0.7	11
565	Circulating VEGF and its soluble receptors sVEGFR-1 and sVEGFR-2 in patients with acute leukemia. European Cytokine Network, 2003, 14, 149-53.	1.1	31
566	Langerhans Cell Histiocytosis in a Patient with Systemic Lupus Erythematosus: A Clonal Disease Responding to Treatment with Cladribine, and Cyclophosphamide. Leukemia and Lymphoma, 2002, 43, 2041-2046.	0.6	9
567	Acute Lymphoblastic Leukemia in Adult First Manifested as Severe Aplastic Anemiaâ€™Role of Molecular Analysis in Correct Diagnosis. Leukemia and Lymphoma, 2002, 43, 1147-1152.	0.6	3
568	The Role of Nucleoside Analogues in the Treatment of Chronic Lymphocytic Leukemia-Lessons Learned from Prospective Randomized Trials. Leukemia and Lymphoma, 2002, 43, 537-548.	0.6	22
569	Aggressive Primary Plasma Cell Leukemia with Skin Manifestations, Trisomy 8 and Molecular Oligoclonal Features. Leukemia and Lymphoma, 2002, 43, 1067-1073.	0.6	12
570	Human leukocyte antigens class II and tumor necrosis factor genetic polymorphisms are independent predictors of non-Hodgkin lymphoma outcome. Blood, 2002, 100, 3037-3040.	0.6	78
571	The Search for Optimal Treatment in Relapsed and Refractory Acute Myeloid Leukemia. Leukemia and Lymphoma, 2002, 43, 281-291.	0.6	32
572	G-CSF Administered in Time-sequenced Setting During Remission Induction and Consolidation Therapy of Adult Acute Lymphoblastic Leukemia has Beneficial Influence on Early Recovery and Possibly Improves Long-term Outcome: A Randomized Multicenter Study. Leukemia and Lymphoma, 2002, 43, 315-325.	0.6	31
573	Anthracyclines potentiate activity against murine leukemias L1210 and P388 in vivo and in vitro. European Journal of Haematology, 2002, 68, 370-375.	1.1	17
574	Re-treatment with cladribine-based regimens in relapsed patients with B-cell chronic lymphocytic leukemia. Efficacy and toxicity in comparison with previous treatment. European Journal of Haematology, 2002, 69, 27-36.	1.1	13
575	High-dose chemotherapy with autologous stem cell transplantation is an effective treatment of primary refractory Hodgkin's disease. Retrospective study of the Polish Lymphoma Research Group. Bone Marrow Transplantation, 2002, 30, 29-34.	1.3	18
576	Cladribine combined with cyclophosphamide is highly effective in the treatment of chronic lymphocytic leukemia. The Hematology Journal, 2002, 3, 244-250.	2.0	40

#	ARTICLE	IF	CITATIONS
577	Distribution of allelic variants of functional C3435T polymorphism of drug transporter MDR1 gene in a sample of Polish population. Polish Journal of Pharmacology, 2002, 54, 495-500.	0.3	22
578	Lymphoplasmacytic lymphoma with monoclonal gammopathy-related pseudo-Gaucher cell infiltration in bone marrow and spleen—diagnostic and therapeutic dilemmas. Leukemia and Lymphoma, 2002, 43, 2343-50.	0.6	17
579	Cladribine in the Treatment of Chronic Lymphocytic Leukemia. Leukemia and Lymphoma, 2001, 40, 551-564.	0.6	46
580	Low-Grade Non-Hodgkin's Lymphoma in a Patient with Systemic Lupus Erythematosus. Leukemia and Lymphoma, 2001, 41, 659-667.	0.6	6
581	Altered Expression of Nuclear Non-Histone Protein (P44/46) in Different Stages of B-Chronic Lymphocytic Leukemia. Leukemia and Lymphoma, 2001, 41, 635-642.	0.6	1
582	Does Intensive Treatment with High Dose Chlorambucil and Prednisone as First Line and Cladribine as Second Line Influence the Survival of the Patients with Chronic Lymphocytic Leukemia?. Leukemia and Lymphoma, 2001, 41, 545-557.	0.6	9
583	Lymphocytes TÎ³Î¶ in clinically normal skin and peripheral blood of patients with systemic lupus erythematosus and their correlation with disease activity. Mediators of Inflammation, 2001, 10, 179-189.	1.4	44
584	Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia. Leukemia, 2001, 15, 1510-1516.	3.3	35
585	Cladribine in combination with mitoxantrone and cyclophosphamide(CMC) in the treatment of heavily pre-treated patients with advanced indolent lymphoid malignancies. European Journal of Haematology, 2001, 66, 188-194.	1.1	30
586	Richter's Syndrome Following Cladribine Therapy for Chronic Lymphocytic Leukemia First Manifested as Pathologic Fracture of the Femur. Leukemia and Lymphoma, 2001, 42, 789-796.	0.6	20
587	Cladribine with or without prednisone in the treatment of previously treated and untreated B-cell chronic lymphocytic leukaemia - updated results of the multicentre study of 378 patients. British Journal of Haematology, 2000, 108, 357-368.	1.2	77
588	Influence of gemcitabine (2â€²,2â€²-difluoro-deoxycytidine) and 2-chlorodeoxyadenosine on growth of normal and leukemic cells in vitro. European Journal of Haematology, 2000, 65, 317-321.	1.1	9
589	Amifostine and 2-CdA: a novel purging strategy in CML autografting?. European Journal of Haematology, 2000, 64, 347-349.	1.1	1
590	Pituitaryâ€™adrenocortical responses to the chronic administration of granulocyte colony-stimulating factor in rats. Journal of Neuroimmunology, 2000, 102, 73-78.	1.1	8
591	Combination Regimen of Cladribine (2-Chlorodeoxyadenosine), Cytarabine and G-CSF (CLAG) as Induction Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia. Leukemia and Lymphoma, 2000, 39, 121-129.	0.6	54
592	Dexamethasone does not enhance antileukemic activity of cladribine in mice with leukemias L1210 and P388. Neoplasma, 2000, 47, 168-71.	0.7	1
593	Atypical Chronic Myelogenous Leukemia Following Immunosuppressive Therapy for Severe Aplastic Anemia. Leukemia and Lymphoma, 1999, 35, 193-199.	0.6	1
594	Serum Levels of IL-6 Type Cytokines and Soluble IL-6 Receptors in Active B-Cell Chronic Lymphocytic Leukemia and in Cladribine Induced Remission. Mediators of Inflammation, 1999, 8, 277-286.	1.4	23

#	ARTICLE	IF	CITATIONS
595	Circulating TCR β Cells in the Patients with Systemic Lupus Erythematosus. Mediators of Inflammation, 1999, 8, 305-312.	1.4	20
596	Circulating IL-6-type cytokines and sIL-6R in patients with multiple myeloma. British Journal of Haematology, 1999, 105, 412-419.	1.2	47
597	2-Chlorodeoxyadenosine (Cladribine) in the treatment of patients with chronic lymphocytic leukemia 55 years old and younger. Leukemia, 1999, 13, 518-523.	3.3	38
598	Influence of granulocyte-macrophage colony stimulating factor on pituitary-adrenal axis (PAA) in rats in vivo. Pituitary, 1999, 2, 211-216.	1.6	9
599	A novel B-CLL specific nuclear protein (p44/46). Leukemia Research, 1999, 23, 833-841.	0.4	4
600	Additive Action of Gemcitabine (2 β ,2 β -Difluorodeoxycytidine) and 2-Chlorodeoxyadenosine on Murine Leukemias L1210 and P388. Cancer Investigation, 1999, 17, 95-101.	0.6	14
601	Combination Regimen of 2-Chlorodeoxyadenosine (Cladribine), Mitoxantrone and Dexamethasone (CMD) in the Treatment of Refractory and Recurrent Low Grade Non-Hodgkin's Lymphoma. Leukemia and Lymphoma, 1999, 32, 359-363.	0.6	24
602	2-Chlorodeoxyadenosine (Cladribine) in the Treatment of Elderly Patients with B-Cell Chronic Lymphocytic Leukemia. Leukemia and Lymphoma, 1999, 34, 151-156.	0.6	31
603	2 β -Chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7 β -year experience in Poland. European Journal of Haematology, 1999, 62, 49-56.	1.1	73
604	Cytokines serum levels as the markers of thyroid activation in Graves' disease. Immunology Letters, 1998, 60, 143-148.	1.1	18
605	Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis. Mediators of Inflammation, 1998, 7, 347-353.	1.4	141
606	Activity of 2-chlorodeoxyadenosine (cladribine) in 2-hour intravenous infusion in 94 previously treated patients with low grade non-hodgkin's lymphoma. Leukemia and Lymphoma, 1997, 26, 99-105.	0.6	24
607	Hairy cell leukemia β variant treated with 2-Chlorodeoxyadenosine β a report of three cases. Leukemia and Lymphoma, 1997, 25, 381-385.	0.6	35
608	The influence of recombinant human tumor necrosis factor β and its muteins used alone or in combination with 2-chlorodeoxyadenosine on normal and leukemic hematopoiesis in vitro. Leukemia Research, 1997, 21, 857-865.	0.4	4
609	Autoimmune haemolytic anaemia in patients with chronic lymphocytic eukaemia treated with 2 β -chlorodeoxyadenosine (cladribine). European Journal of Haematology, 1997, 58, 109-113.	1.1	43
610	2 β -Chlorodeoxyadenosine (cladribine) β -related eosinophilia in patients with lymphoproliferative diseases. European Journal of Haematology, 1997, 59, 216-220.	1.1	15
611	The Comparison of 2-Chlorodeoxyadenosine (2-Cd A) in Combination with Interferon β (IFN β) or Interferon β (IFN β) on Granulocyte-Macrophage Progenitor Cells (CFU-GM) and Clonogenic Blasts in (CFU-L) In Vitro Cultures. Leukemia and Lymphoma, 1996, 21, 161-168.	0.6	12
612	Tumour necrosis factor β (TNF- β), interleukin-6 (IL-6) and their soluble receptors (sTNF- β -Rp55 and sIL-6R) serum levels in systemic lupus erythematoses. Mediators of Inflammation, 1996, 5, 435-441.	1.4	12

#	ARTICLE	IF	CITATIONS
613	Interaction of anthracyclines with human erythrocytes at hyperthermic temperature. <i>International Journal of Pharmaceutics</i> , 1996, 135, 167-176.	2.6	12
614	Fulminant 2-Chlorodeoxyadenosine-Related Peripheral Neuropathy in a Patient with Paraneoplastic Neurological Syndrome Associated with Lymphoma. <i>Leukemia and Lymphoma</i> , 1996, 21, 343-346.	0.6	6
615	2-Chlorodeoxyadenosine (2-CdA) in 2-Hour Versus 24-Hour Intravenous Infusion in the Treatment of Patients with Hairy Cell Leukemia. <i>Leukemia and Lymphoma</i> , 1996, 22, 107-111.	0.6	65
616	Intermittent 2-hour intravenous infusions of 2-chlorodeoxyadenosine in the treatment of 110 patients with refractory or previously untreated B-cell chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 1996, 22, 509-14.	0.6	10
617	The influence of 2- chlorodeoxyadenosine in combination with tumour necrosis factor- $\hat{1}\pm$ or its mutein on murine leukaemias L1210 and P388. <i>Mediators of Inflammation</i> , 1995, 4, 205-208.	1.4	1
618	Effect of granulocyte-macrophage colony stimulating factor and granulocyte colony stimulating factor on melatonin secretion in rats In vivo and in vitro studies. <i>Journal of Neuroimmunology</i> , 1995, 56, 187-190.	1.1	18
619	The Influence of 2-Chlorodeoxyadenosine (2-CdA) Alone and in Combination with Cyclophosphamide or Methotrexate on Normal and Leukemic Hematopoiesis. <i>Advances in Experimental Medicine and Biology</i> , 1995, 370, 129-130.	0.8	2
620	A comparison of the Antileukaemic Effects of Recombinant Human Tumour Necrosis Factor- $\hat{1}\pm$ and its Muteins on Leukaemia L1210 and Leukaemia P388 in Mice. <i>Mediators of Inflammation</i> , 1994, 3, 411-414.	1.4	2
621	The interaction of 2-chlorodeoxy adenosine (2-CDA) and interferon $\hat{1}\pm$ (IFN- $\hat{1}\pm$) on normal and myeloid leukemia hematopoiesis in vitro. <i>Leukemia Research</i> , 1994, 18, 275-281.	0.4	10
622	Antigenic determinants on myeloid leukaemia colony-forming cells resemble those of normal myeloid progenitor cells and differ from those of circulating blast cells. <i>British Journal of Haematology</i> , 1986, 64, 133-148.	1.2	7
623	Antigenic characteristics of circulating CFU-GM in chronic granulocytic leukaemia resemble those of CFU-GM in normal marrow and differ from those in normal blood. <i>Leukemia Research</i> , 1985, 9, 1023-1029.	0.4	8
624	MONOCLONAL ANTIBODIES REACTING WITH MYELOID CELLS. <i>British Journal of Haematology</i> , 1985, 61, 1-9.	1.2	16